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2 INTRODUCTION 
 
2  INTRODUCTION 
2.1 Background and aim of the study 
Angiogenesis, the process of vascular outgrowth by sprouting from pre-existing vessels, is 
fundamental for the vascularization during embryonic development. During adultness, it is 
required for menstruation cycle and wound healing. However, angiogenesis is also involved 
in pathological processes, including diabetic retinopathy, arthritis, psoriasis, and tumor 
growth.1 Consequently, the search for anti-angiogenic compounds and their molecular targets 
has been intensified during the recent years.2, 3 Compounds that control the first step in the 
angiogenic cascade, the response of endothelial cells to growth factors have already been 
established. They include the monoclonal antibody Bevacizumab (Avastin®, Roche), and 
kinase inhibitors like Sunitinib (Sutent®, Pfizer) and Sorafenib (Nexavar®, Bayer). However, 
compounds targeting the following steps, e.g. endothelial cell migration or tube formation, 
respectively, are still missing.  
Recently, anti-angiogenic agents have been shown to synergize with classical anti-
proliferative drugs in cancer therapy.4 Following this line of thought, it is surprising that the 
anti-angiogenic potential of a class of compounds, the inhibitors of cyclin dependent kinases 
(Cdks) – initially designed for the control of cell cycle progression – has never been studied in 
detail. Cdk inhibitors comprise such classical and well-characterized compounds as 
roscovitine, flavopiridol, and 7-hydroxystraurosporine. Roscovitine (Seliciclib, CYC202) is 
an orally available small molecule Cdk inhibitor that is currently evaluated in phase 2b 
clinical trials concerning cancer therapy (“Efficacy Study of Oral Seliciclib to Treat Non-
Small Cell Lung Cancer”).5 A special feature of roscovitine is its grade of specificity: in 
contrast to many other small molecule kinase inhibitors, this compound only inhibits Cdk1, 
Cdk2, Cdk5, Cdk7, and Cdk9 to a relevant degree, other kinases are not targeted.6, 7  
Cdk5 is an unusual member of the Cdk family. In contrast to the cell cycle-related Cdks (e.g. 
Cdk1, 2, 4 or 6) which regulate the main cell cycle transitions,8 Cdk5 is not implicated in cell 
cycle control. Since it was discovered in the 1990s, it has emerged as a crucial regulator of 
neuronal migration in the developing nervous system.9 In neurons, Cdk5 regulates cell 
migration, adhesion, and axon guidance by influencing the cytoskeleton, i.e. actin dynamics 
and microtubule organization and transport, via phosphorylation of various substrates. 
Recently, the biological and molecular similarities between nervous and vascular systems 
have attracted a lot of attention, since repulsive cues first discovered in the neuronal system to 
inhibit axon migration were shown to inhibit angiogenesis as well, utilizing similar 
mechanisms.10 Apparently, vascular and neuronal cells use similar signals and principles to 
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differentiate, grow and navigate.11 Thus, various ligand/receptor pairs described to regulate 
neuronal guidance have been implicated in angiogenesis as well.2, 10  
These parallels concerning the regulation of the growth of nerves and blood vessels led us to 
the hypothesis that Cdk5 might be involved in the regulation of endothelial cell migration and 
angiogenesis, and that, consequently, the Cdk inhibitor roscovitine and its derivatives have 
anti-angiogenic properties. 
 
 
 
Thus, the aims of this study were  
1.  to elucidate potential anti-angiogenic effects of the Cdk inhibitor roscovitine and 
its derivatives LGR561, LGR848, and LGR849, to compare their potency and 
 
2.  to characterize the role of Cdk5 in endothelial cell migration and angiogenesis. 
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2.2 Cyclin dependent kinases 
2.2.1 Functions 
Cyclin dependent kinases (Cdks) are a family of small serine/threonine kinases that associate 
with cyclins. Cdk/cyclin complexes phosphorylate target proteins to induce cellular responses. 
Cdks were initially characterized about 30 years ago. Nurse et al. identified a gene in fission 
yeast that controlled entry into mitosis (cdc2 or Cdk1),12 while Masui and Smith discovered a 
complex called maturation-promoting factor (MPF) in amphibian oocytes.13, 14 Henceforward, 
Cdks have become generally known as master regulators of the main transitions of the 
eukaryotic cell cycle.15 Cell cycle related Cdks include Cdk1, Cdk2, Cdk3, Cdk4, Cdk6, and 
Cdk7 as a component of the Cdk activating kinase (CAK), according to Figure 1.8, 16  
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Figure 1  The cell cycle and its regulation by cell cycle related Cdks. Cdk4 and Cdk6 associate with 
cyclinD during G1 phase. Cdk2 is activated by cyclinE during DNA synthesis and by cyclinA during  
S/G2 transition. Cdk1 associates with cyclinA during G2 phase and with cyclinB at G2/M transition, respectively.  
 
However, Cdk5, Cdk7, Cdk9, Cdk10, Cdk11, Cdk12, and Cdk13 are not directly implicated 
in the control of cell cycle transitions. Cdk5 is a crucial regulator of neuronal migration and 
development.9 Cdk7 is a component of the CAK complex that activates other Cdks by 
phosphorylation.17 Cdk7 also is involved in transcription control by phosphorylating the  
C-terminal domain of the large subunit of RNA-polymerase II, just as Cdk8, and Cdk9.18 
Cdks which regulate RNA splicing include Cdk10, Cdk11, Cdk12, and Cdk13.16 In spite of 
their different biological functions, the family members share about 40% sequence identity. 
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2.2.2 Regulation 
Cdks are regulated in different ways. For activation, the monomeric Cdk requires the 
association with a cyclin regulatory subunit. Originally, cyclins were defined as proteins 
whose levels oscillate during the cell cycle. Today, they are more accurately defined as 
members of a family of structurally related proteins that bind to and activate Cdks. Each Cdk 
interacts with a subset of cyclins, and mammalian cyclins can interact with several Cdks.15  
In addition to their association with cyclins, Cdk activation requires phosphorylation of a 
conserved threonine by CAK (i.e. Thr160 for Cdk2, Thr161 for Cdk1).19 Phosphorylation of a 
conserved threonine-tyrosine pair (Thr14 and Tyr15) mediated by Wee1 and Myt1 protein 
kinases inhibits Cdk-cyclin complexes. Cdc25 phosphatases reactivate Cdks by 
dephosphorylating Thr14 and Tyr15. Furthermore, Cdks are inhibited by binding to Cdk 
inhibitors (CKIs). Two classes of CKIs exist: the Cip/Kip-family is composed of the three 
members p21waf1/kip1, p27kip1, and p57kip1 and the INK4 family includes the four members p15, 
p16, p18, and p19.20  
 
Mat1
Cdk
Cdk
P
Cdk7
Cdk
cyclin
CdkP
P
Cip/Kip
INK4
inactiveinactive
active
Wee1
Myt1
cdc25
CAK
inactivating
phosphorylation
activating
phosphorylation
association
with cyclins
Inhibition
by CKIs
cyclin
cyclin
cyclin
cyclinH
 
 
Figure 2  Regulation of Cdks. Activation of Cdks requires association with a cyclin regulatory subunit 
and phosphorylation by CAK. Cdks are inactivated by Wee1/Myt1-mediated phosphorylation and by association 
with Cip/Kip- or INK4-family members. 
 
In summary, the different Cdk/cyclin complexes are required to catalyze the phosphorylation 
of distinct protein substrates which in turn regulate key cellular processes including cell cycle 
transitions, transcription, RNA splicing, apoptosis, and neuronal development.  
 
 
6  INTRODUCTION 
2.3 Cyclin dependent kinase 5 (Cdk5) 
Cdk5 belongs to the family of Cdks. Despite having 60% sequence identity with cell cycle 
related Cdks1 and 2, Cdk5 is not implicated in cell cycle control. Since it was discovered in 
the 1990s, it has emerged as a crucial regulator of neuronal migration in the developing 
nervous system. Despite its important role in the nervous system, Cdk5 is ubiquitously 
expressed, pointing to the question about its function in other tissues.  
Cdk5 is a proline-directed kinase that phosphorylates serines and threonines immediately 
upstream of a proline residue. The consensus sequence for Cdk5 is (S/T)PX(K/H/R). S and T 
represent the phosphorylatable serine or threonine residues, X is any amino acid and P is the 
proline in the +1 position.9  
 
2.3.1 Regulation of Cdk5 
Although the regulation of Cdk5 shares common features with the mitotic Cdks, important 
differences exist. Like other Cdks, monomeric Cdk5 shows no enzymatic activity and requires 
association with a regulatory subunit for activation. Cdk5 associates with and gets activated 
by the two non-cyclin proteins p35 and p39. Both share about 57% amino acid identity and 
are themselves regulated by transcription and ubiquitin-mediated degradation. A 
myristoylation motif targets p35 and p39 to cell membranes and cell periphery, dictating the 
subcellular distribution of Cdk5.9  
In contrast to mitotic Cdks which are inhibited by phosphorylation at Tyr15, phosphorylation 
of Cdk5 at Tyr15 by the tyrosine kinase c-Abelson (c-Abl) increases its activity. The role of 
phosphorylation of Cdk5 by CAK is not entirely clear. CAK was shown to activate Cdk5 by 
phosphorylation at Ser159.21 However, phosphorylation of Cdk5 at Ser159 also was described 
as dispensable.22, 23  
Moreover, Cdk5 is not inhibited by CKIs including p21waf1/kip1 and p27kip1. An overview over 
the regulation of Cdk5 is given in Figure 3. 
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Figure 3  Regulation of Cdk5. Like the mitotic Cdks, activation of Cdk5 requires the association with a 
regulatory subunit. Cdk5 associates and is activated by the two non-cyclin proteins p35 and p39. In contrast to 
the mitotic Cdks, Cdk5 gets activated via phosphorylation at Tyr 15 by c-Abl. Furthermore, Cdk5 is not inhibited 
by CKIs.The role of phosphorylation at Ser159 by CAK is not entirely clear.  
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2.3.2 Function of Cdk5 in the nervous system 
Cdk5 has been characterized as a signalling molecule with central functions in the nervous 
system. Mice that are deficient for Cdk5 show perinatal lethality with defects in neuronal 
layering of many brain structures, including the cerebral cortex, the hippocampus, the 
cerebellum, and the olfactory bulb, indicating an impact of Cdk5 on neuronal cell 
migration.24-26 In the central nervous system, Cdk5 is essential for the regulation of the 
cytoarchitecture during brain development, neuronal migration, adhesion, axon guidance, 
membrane transport, neuronal survival, dopaminergic signalling, drug addiction, and synaptic 
function according to Figure 4. 
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Figure 4  Cellular processes regulated by Cdk5.  
 
Deregulation of Cdk5 leads to neurodegenerative diseases including Alzheimer’s disease and 
amyotrophic lateral sclerosis (ALS) based on the hyperphosphorylation of the microtubule 
associated protein Tau by the p25-Cdk5 complex. Neurotoxic insults induce the cleavage of 
p35 into p25 that in turn is neurotoxic by mislocalizing Cdk5 to the cytoplasm, causing 
sustained activation. Thus, association of Cdk5 with p25 leads to hyperphosphorylation of 
Tau protein, cytoskeletal disruption, and neuronal death.9 
The crucial role of Cdk5 in neuronal migration is based on its involvement in the regulation of 
the cytoskeleton. Cdk5 regulates actin dynamics as well as microtubule stability and transport 
via phosphorylation of various downstream substrates. Some of the substrates of Cdk5 that 
are linked to cell migration and motility are summarized in Table 1.  
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Table 1   Substrates of Cdk5 which are implicated in cellular motility. 
 
Cdk5  
substrate 
Phosphorylation 
site(s) 
Putative function of the 
phosphorylation 
Reference
 
PAK1 Thr212 Inhibits PAK1 activity, regulation of actin dynamics, neuronal morphology 
27, 28 
Src Ser75 Regulation of cell adhesion,  actin dynamics, integrin signalling 
29 
WAVE1 Ser310, Ser397, Ser441 
Regulation of actin polymerization and 
dendritic spine morphology 
30 
ephexin1  Thr41, Ser139 
Increases ephexin1 activity towards RhoA, 
regulation of dendritic spine retraction, 
modulation of actin dynamics 
31 
Neurabin-I Ser95 
Regulation of the assembly of Neurabin-I 
with F-actin, neuronal morphology, and 
cortical migration  
32 
p27kip Ser10, Thr187 Stabilization of p27
kip, regulation of actin 
organization, neuronal migration 
33 
Disabled-1 Ser400, Ser491 Inhibits interaction with CIN85, regulation of actin dynamics 
34 
FAK Ser732 Regulation of microtubule organization, nuclear movement, neuronal migration 
35 
Doublecortin Ser297 Regulation of microtubule polymerization, neuronal migration 
36 
MAP1B multiple Regulation of microtubule stability 37, 38 
Tau multiple  Disorganization of microtubules 39, 40 
Nudel Ser198, Ser231, Thr219 
Regulation of NUDEL distribution, axonal 
morphology, dynein behaviour, and 
microtubule organization 
41 
SIRT2 Ser331 
Inhibits SIRT2 activity, regulation of 
microtubule stability, cell adhesion and 
motility, neurite outgrowth 
42 
Dynamin I Ser774, Ser778 Synaptic vesicle endocytosis,  axonal transport 
43 
β-catenin Tyr654 (indirect) Ser191, Ser246 Regulation of cell adhesion 
44-46 
RasGRF1 Ser732 RasGRF1 degradation, regulation of neuronal nuclear organization 
47 
RasGRF2 Ser737 
Downregulation of Rac activity and 
ERK1/2 activation, alters RasGRF2 and 
MAP1B distribution in neurons 
48 
 
In summary, Cdk5 regulates neuronal cell migration, adhesion, and axon guidance by 
influencing microtubules and the actin cytoskeleton via phosphorylation of various substrates. 
To date, all these actions have only been examined in neuronal cells. 
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2.4 Cyclin dependent kinase inhibitors 
Aberrations of cell cycle progression occur in the majority of human malignancies.49 In 
cancer cells, there are fundamental alterations in the control of cell division, resulting in 
unrestricted cell proliferation.50 Thus, to target cell cycle pathways has become an attractive 
approach in oncology.51 Based on the crucial role of Cdks in regulating cell cycle transitions 
and, thus, cell proliferation, Cdk inhibitors have been designed as promising anti-proliferative 
agents for cancer therapy. During recent years, a great variety of chemical inhibitors of Cdks 
has been identified and characterized. Cdk inhibitors are small molecules which directly 
inhibit Cdks by competing with ATP for the binding at the catalytic site of the kinase. 
Although they all share the same principle of action, their selectivity towards the different 
Cdks varies greatly.52 Some Cdk inhibitors currently are evaluated in clinical trials, including 
such classical and well-characterized compounds like roscovitine, flavopiridol, and 7-
hydroxystraurosporine.5, 50, 53  
 
2.4.1 Roscovitine (Seliciclib, CYC202) 
Roscovitine (Seliciclib, CYC202) belongs to the family of 2, 6, 9-trisubstituted purines that 
encompasses some of the first Cdk inhibitors which have been described. In 1997, roscovitine 
was developed as a close analogue to the modestly potent Cdk inhibitor olomoucine and 
showed improved potency and selectivity in inhibiting Cdks.6 Thus, a special feature of 
roscovitine is its relative specificity. In contrast to many other small molecule kinase 
inhibitors that also inhibit kinases not belonging to the Cdk family, roscovitine only inhibits 
Cdk1, Cdk2, Cdk5, Cdk7, and Cdk9 to a relevant degree.6, 7 Structure/activity studies 
elucidated that the (R)-stereoisomer is about twice as potent in inhibiting Cdk1/cyclinB than 
the (S)-stereoisomer.54 The chemical structure of (R)-roscovitine is displayed in Figure 5. 
 
N
N
N
N
NH
NH
OH
(R)-Roscovitine
(Seliciclib, Cyc202)
*
 
 
Figure 5  Chemical structure of roscovitine. Roscovitine competes with ATP for binding to the 
catalytic site of Cdks, due to its structural similarity. Thus, the purine portion binds to the adenine binding pocket 
of Cdks. The benzyl function enables the inhibitor to make contacts with the enzyme. 
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In recent years, the (R)-stereoisomer of roscovitine has developed to one of the prior used and 
most frequently studied Cdk inhibitors. Thus, roscovitine has been evaluated for its effects on 
a wide variety of cultured cancer cell lines. Two major effects have been described: 
roscovitine leads to an arrest in cell cycle progression and it induces cell death in most cancer 
cell lines. The anti-tumor activity of roscovitine has also been studied in various human tumor 
xenografts established on nude mice. Roscovitine was well tolerated when administerd orally, 
intravenously, as well as intraperitoneally and induced delay of tumor growth. In detail, 
roscovitine was most active in inhibiting the proliferation of colon, non-small cell lung, 
breast, and prostate cancer. Furthermore, roscovitine has been evaluated in several phase I 
clinical trials. Cyclacel is currently conducting a phase 2b clinical trial to test the efficacy and 
safety of roscovitine in cancer therapy. The study is evaluating roscovitine in patients with 
non-small cell lung cancer (NSCLC). (“Efficacy Study of Oral Seliciclib to Treat Non-Small 
Cell Lung Cancer”).5 
 
2.4.2 Derivatives of roscovitine: LGR561, LGR848, and LGR849 
LGR561, LGR848, and LGR849 are close analogues of roscovitine which have been 
synthesized by Vladimir Krystof (Palacky University & Institute of Experimental Botany, 
Czech Republic). They have been developed to optimize the selectivity and potency of 
roscovitine in an EU project collaboration (PROKINASE No 503467). LGR561 is a (S)-
stereoisomer with an additional ortho-hydroxyl-group in the benzyl function. LGR848 
represents the (R)-stereoisomer and LGR849 the (S)-stereoisomer of a racemate with an 
additional ortho-hydroxyl-group and a meta-methoxy-group in the benzyl function (Figure 6). 
 
Compound R1 R2 stereoisomer
LGR561 -OH -H (S)
LGR848 -OH -OCH3 (R)
LGR849 -OH -OCH3 (S)
N
N
N
NNH
OH
NH
R1
R2
*
 
 
Figure 6  Chemical structures of LGR561, LGR848, and LGR849. All compounds are close 
analogues of the mother substance roscovitine. LGR561 only differs in residue R1 by the presence of an 
additional ortho-hydroxyl-group in the benzyl function. LGR848 and LGR849 differ in R1 and R2 by an 
additional ortho-hydroxyl-group and a meta-methoxy-group in the benzyl function. 
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2.5 Angiogenesis 
Angiogenesis is the process of vascular growth by sprouting from pre-existing vessels. It is 
fundamental for the vascularization during embryonic development. During adulthood, most 
blood vessels remain quiescent and angiogenesis occurs only in the cycling ovary and in the 
placenta during pregnancy. As endothelial cells retain their ability to divide rapidly in 
response to physiological stimuli (e.g. hypoxia), angiogenesis is reactivated during wound 
healing and repair. Physiologically, the onset of angiogenesis is regulated by a balance 
between pro-angiogenic and anti-angiogenic factors. In many pathological processes, 
including diabetic retinopathy, arthritis, psoriasis, and tumor growth, the pro-angiogenic 
stimuli become excessive and the balance between stimulators and inhibitors is disrupted, 
resulting in the angiogenic switch and leading to inappropriate vessel growth.3 During tumor 
growth, angiogenesis is required for proper nourishment and removal of metabolic waste from 
tumor sites, and therefore accounts for tumor survival and proliferation.1 
 
2.5.1 Angiogenic cascade 
Angiogenesis involves a cascade of events with the migration of endothelial cells playing a 
central role.55 Endothelial cells get activated by angiogenic factors such as VEGF-A, VEGF-
C, bFGF, angiopoietins, interleukin-8, and PDGF, which are released by the diseased tissue 
(tumor) into the surrounding area. These factors activate resident endothelial cells by binding 
to specific receptors on their surface. Thus activated, endothelial cells produce molecules that 
locally degrade the basement membrane of the parent vessel and of the surrounding 
extracellular matrix (ECM). They begin to proliferate, show increased survival, change their 
adhesive properties, and vessel sprouting occurs.56 Following appropriate guidance cues 
(growth factors like VEGF or bFGF), endothelial cells migrate towards the diseased tissue 
(tumor). Once the growing sprout of endothelial cells reaches its target (tumor), the tips of 
other sprouts, or existing capillaries, the formation of capillary tubes is induced. The primary 
sprout converts into a functional, blood carrying vessel. This process involves the adhesion of 
endothelial cells to the surrounding matrix, the formation of tight junctions, the deposition of 
a new basement membrane and the recruitment of other cells like pericytes or smooth muscle 
cells.57 An overview over the different steps of the angiogenic cascade is displayed in  
Figure 7. 
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Figure 7  Angiogenic cascade. Endothelial cells get activated by angiogenic stimuli. They proliferate, 
show increased survival, degrade the extracellular matrix (ECM), and directly migrate towards the tumor. 
Finally, new tubes are formed and vessels are stabilized, leading to vascularization of the tumor.  
 
The structure of tumor vasculature strongly differs from normal blood vessels. Tumor vessels 
follow tortuous paths and are highly disorganized, including an irregular shape with uneven 
diameter, and excessive branching and shunts. They are characterized by increased 
permeability (leakiness), abnormal blood flow, a discontinuous basement membrane and an 
unusual pericyte coat.58 
Recently, the biological and molecular similarities between nervous and vascular systems 
have attracted a lot of attention, since repulsive cues first discovered in the neuronal system to 
inhibit axon migration, were also found to inhibit angiogenesis utilizing similar 
mechanisms.10 Vascular and neuronal cells were shown to use similar signals and principles 
to differentiate, to grow, and to navigate.11 Thus, various ligand/receptor pairs described to 
regulate neuronal guidance have been implicated in angiogenesis as well. They include 
semaphorin/neuropilin, ephrin/Eph, Slit/roundabouts (Robo), and Netrin/uncoordinated-5 
(UNC5)2, 10. These parallels concerning the regulation of the growth of nerves and blood 
vessels not only link vascular biology and neuroscience, they furthermore promise to 
accelerate the finding of new mechanistic insights and therapeutic opportunities. 
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2.6 Endothelial cell migration 
The migration of endothelial cells is essential to angiogenesis. It is a multistep process which 
involves changes in the cytoskeleton, i.e. remodelling of actin filaments and microtubules, 
cell-substrate adhesions, and the extracellular matrix. It is directionally regulated by 
chemotactic (VEGF, bFGF, angiopoietins, ephrins, TNFα), haptotactic (components of ECM 
and integrins), and mechanotactic (fluid shear stress) stimuli and requires the activation of 
several signalling pathways that converge on cytoskeletal remodelling. 55, 59  
 
2.6.1 Cell types 
In endothelial cell migration, a distinction is drawn between two cell types. So called tip cells 
initiate the migration of endothelial cells and lead the endothelial cell sprout by following 
appropriate guidance cues. They are highly migratory and express numerous filopodia and 
lamellipodia that explore the surrounding tissue. In contrast, they show only low proliferative 
activity. Tip cells are followed by trailing cells, called trunk cells or stalk cells. Trunk cells 
maintain the connection to the parent vasculature. They have fewer and shorter filopodia and 
are highly proliferative.  
Only few cells can be selected as tip cells, otherwise the patency of stable blood vessels 
would be lost, resulting in vascular leakage or haemorrhage. Thus, endothelial cells exposed 
to a similar degree of pro-angiogenic stimuli, have to exhibit distinct cellular behaviours. The 
decision whether a cell becomes a tip cell or a trunk cell, is regulated by the Notch/Dll-
signalling pathway.57, 60  
 
2.6.2 Regulation of endothelial cell migration 
Endothelial cell migration can be devided into 5 sequential events. It is initiated by cell 
polarization and actin-dependent protrusion at the leading edge where lamellipodia and 
filopodia are formed. During cellular extension, under the leading edge, new adhesions to the 
substratum are generated. Next, the nucleus and the cell body are translocated forward 
through actomyosin-based contraction forces, mediated by stress fibres linked to focal 
adhesions. Then, retraction fibres pull the rear of the cell forward, adhesions at the rear of the 
cell disassemble, and the trailing edge retracts. The different steps of endothelial cell 
migration are displayed in Figure 8. 
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Figure 8  Steps of endothelial cell migration.  
 
2.6.2.1 Cell polarization 
Cell polarity, i.e. the asymmetric distribution of organelles, proteins, and/or surface 
projections, is substantial for proper cell migration. It is achieved by signalling molecules 
including the family of Rho GTPases, and phosphoinositide-3-kinases (PI3Ks). Cdc42, a 
member of the family of Rho GTPases, affects cell polarity along with the PAR-complex 
(polarity protein partitioning-defective-complex) including PAR6, PAR3, and aPKC. Cdc42 
localizes the Golgi-apparatus and the microtubule organizing centre (MTOC) in front of the 
nucleus, oriented towards the cell front. Cdc42-induced MTOC orientation facilitates the 
polarized organization of microtubules which radiate from the MTOC with their plus-ends 
contacting the actin-rich leading edge as well as targeting focal adhesions in the rear of the 
cell.61 The growth of microtubules stimulates Rac1 activity which mediates actin 
polymerization and lamellipodium formation. Shortening of microtubules stimulates RhoA, 
resulting in stress fibres formation and contraction. In this context, RhoA and Rac1 are 
mutually antagonistic. Thus, during cell migration, microtubules maintain cell polarity by 
proper positioning and stabilization of the leading edge and by contributing to rear 
retraction.62 Cellular asymmetry is thereby regulated by APC proteins and by plus-end-
tracking proteins (+TIPs), including cytoplasmic linker proteins (CLIPs) and CLIP-
associating proteins (CLASPs), which localize and stabilize the ends of microtubules at the 
leading edge and promote microtubule growth.63  
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Figure 9  Microtubule dynamics during cell migration. Growing (red), shrinking (green), and 
stabilized (blue) microtubules radiate from the MTOC. Plus-end tracking proteins (+ tips) are localized to and 
direct growing microtubules. The image is adapted from Galjart.63  
 
2.6.2.2 Extension of membrane protrusions 
The extension of membrane protrusions in direction of migration is essential for a cell to 
migrate. These protrusions can be large, broad lamellipodia or spike-like filopodia. They are 
actin-based structures, driven by polymerization of actin filaments (F-actin) and stabilized by 
adhering to the extracellular matrix (ECM).61 Thus, the constant remodelling of the actin 
cytoskeleton is essential for proper cell migration.55  
Lamellipodia are highly dynamic, broad, sheet-like membrane protrusions formed at the 
leading edge of migrating and spreading cells.64 Lamellipodia are characterized by a dendritic 
network of branched actin filaments which are formed by the actin-related-protein 2/3 
(Arp2/3)-complex, dependent on Rac1. 65 The lamellipodium extends about several 
micrometers (1-3 µm) from the leading edge to the lamellum which connects to the cell body. 
At lamellipodia, spreading and migrating cells form new adhesions which connect the actin 
cytoskeleton to the ECM. This anchors the front of the cell and enables forward crawling. 
Thus, the extension of a lamellipodium is required for proper cell migration.66  
Filopodia are thin finger-like protrusions that contain parallel bundles of actin filaments 
emanating from the lamellipodium or the lamellum. They function as sensors of the 
extracellular environment, either for soluble signals or for other cells.64, 67 Cdc42 regulates the 
formation of filopodia by activation of the formin mDia2 which nucleates parallel actin 
bundles at the plasma membrane.65, 68 
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Figure 10  Membrane protrusions - Lamellipodia and filopodia. Lamellipodia are broad, sheet-like 
protrusions formed by highly branched actin filaments. Filopodia are thin, spike-like protrusions of bundled actin 
filaments. The image is adapted from Heasman and Ridley.65 
 
2.6.2.3 Adhesion assembly and disassembly 
During cellular extension, new adhesions are formed under the leading edge. These structures, 
named focal complexes and focal adhesions, control the integrin-mediated mechanical 
coupling between the actin cytoskeleton and the substrate.69 Integrins are the major family of 
migration promoting receptors. They act as feet of a migrating cell by supporting adhesion to 
the ECM. Via adapters, integrins link the actin filaments of the cell to the ECM. Focal 
complexes are highly dynamic adhesions at the leading edge of migrating cells with high 
adhesion turnover. Depending on Rac1 and Cdc42, they stabilize the lamellipodium by 
attachment to the ECM. Focal adhesions are more stable structures with a slower turnover, 
located at the cell periphery and more centrally in less motile regions. They serve as traction 
sites for migration as the cell moves forward over them. The assembly of focal adhesions 
involves RhoA-stress fibres induced contractility.  
Adhesion disassembly is observed both at the leading edge, where it accompanies the 
formation of new protrusions, and at the rear of the cell, where it allows the cell to detach and 
thus, promotes tail retraction and rear release. Adhesion turnover involves the interaction of 
Rho family GTPases and tyrosine kinases including Src kinases and the focal adhesion kinase 
(FAK), a key signalling component localized at focal adhesions.70  
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Figure 11  Focal adhesion: Interaction site of extracellular matrix, integrins, and the cytoskeleton. 
At focal adhesions, the extracellular matrix is connected to the cytoskeleton via integrins and various adapter 
proteins.69 Activation of integrins results in a variety of intracellular responses including the recruitment of 
adapter proteins (vinculin, talin, α-actinin) and several cytoplasmic protein tyrosine kinases like members of the 
Src family kinases and the focal adhesion kinase (FAK). 
 
2.6.2.4 Cell contraction 
Cell contraction is mediated by the formation of stress fibres, i.e. contractile bundles of actin 
and myosin filaments connected with focal adhesions.66 The force transmitted by stress fibres 
to focal adhesions mediates the translocation of the nucleus and the cell body towards the cell 
front and enables the retraction of the rear of the cell. Cell contraction is regulated by the 
RhoA-ROCK-MLC pathway via stress fibres formation. 
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2.6.3 Rho GTPases 
The family of Rho GTPases is crucial for the regulation of the actin cytoskeleton in various 
cell types. They coordinate the cellular responses required for cell migration.59, 71 20 Rho 
family proteins have been identified in humans so far. RhoA, Rac1, and Cdc42 are the most 
prominent members and have been the most widely studied for their effects on cell migration. 
 
2.6.3.1 Regulation 
Rho GTPases cycle between a GTP-bound (active) and a GDP-bound (inactive) 
conformation. In the GTP-bound form, they interact with and activate downstream target 
proteins to induce cellular responses. The activity of Rho GTPases is regulated by guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). GEFs stimulate 
the release of GDP and allow GTP to bind, thus activating the GTPase. GAPs catalyze GTP 
hydrolysis, converting the protein to the GDP-bound inactive conformation. Moreover, 
several Rho GTPases interact with guanine nucleotide dissociation inhibitors (GDIs), which 
prevent their association with the plasma membrane and downstream targets (Figure 12).59, 67  
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Figure 12  Regulation of Rho GTPases. Rho family proteins are active when bound to GTP and inactive 
when bound to GDP. They are activated in response to extracellular signals (i.e. cytokines, growth factors, 
extracellular matrix proteins). Activation is catalyzed by guanine nucleotide exchange factors (GEFs) and 
inactivation by GTPase activating proteins (GAPs). Furthermore, several Rho GTPases bind to guanine 
nucleotide dissociation inhibitors (GDIs) in the cytoplasm and are inactive in this complex. Bound to GTP, they 
interact with downstream target proteins and induce cellular responses.  
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2.6.3.2 Rac1 
Rac1 is active at the cell front of migrating cells. It is a pivotal regulator of the extension of 
lamellipodia.59 Rac1 mediates the polymerization of lamellipodial branched actin filaments 
via the Wiskott-Aldrich syndrome protein (WASP)-family verprolin-homologues protein 
(WAVE) complex. WAVE activates the Arp2/3-complex which nucleates new actin filaments 
from the side of an existing filament, resulting in a branched actin network, characteristic for 
lamellipodia. 64, 67 Rac1 also activates p21-activated kinases PAK1, PAK2, and PAK3. PAKs 
are serine/threonine kinases that phosphorylate and activate LIM kinases LIMK1 and LIMK2 
which in turn phosphorylate and inactivate cofilin. Unphosphorylated cofilin stimulates 
severing and depolymerization of F-actin in lamellipodia.67 Rac1 also is required for the 
targeting of cortactin to the cortical actin network. Cortactin is an Arp2/3 and F-actin binding 
protein and potentiates the nucleation of new actin filaments, playing a pivotal role in 
lamellipodia protrusion and integrity.72 Tyrosine-phosphorylation of cortactin, required for 
efficient cell motility, is dependent on the targeting of cortactin to the cortical actin network 
and is regulated by the activation state of Rac1.73 An overview over Rac1 signalling pathways 
is given in Figure 13. 
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Figure 13  Rac1 signalling. Rac1 is active at the leading edge of a migrating cell, where it regulates the 
formation of lamellipodia. 
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2.6.3.3 Cdc42 
Just as well as Rac1, Cdc42 also is active at the leading edge of migrating cells. Cdc42 
regulates the formation of filopodia by activation of the formin mDia2.67 Formins nucleate 
parallel actin bundles, generating filopodia.68 Cdc42 also contributes to Rac1-mediated 
lamellipodium extension by organizing microtubules to the actin-rich leading edge, where 
microtubule growth stimulates Rac1 activation.67 Furthermore, Cdc42 stimulates the 
formation of WASP and N-WASP proteins, which activate the Arp2/3 complex. Besides 
Rac1, it also activates the PAK-LIMK-cofilin pathway. Figure 14 displays Cdc42 signalling 
pathways. 
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Figure 14  Cdc42 signalling. Cdc42 is also active at the cell front. It regulates formation of filopodia. 
Furthermore, it is implicated in formation of lamellipodia via influencing Rac1.  
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2.6.3.4 RhoA 
In contrast to Rac1 and Cdc42, RhoA is active at the sides and the rear of the cell, associated 
with stress fibre formation and cell body contraction. RhoA acts via Rho-kinases (ROCKs) to 
affect the phosphorylation and the activation of myosin light chain (MLC), both by 
phosphorylating MLC and inhibiting MLC-phosphatase (MLCP). Phosphorylated myosin II 
assembles into fibres that associate with actin filaments to form contractile stress fibres. 
Furthermore, RhoA activates the assembly of parallel actin bundles (stress fibres) via mDia2. 
Like PAK, ROCK also activates LIMKs to inhibit cofilin-mediated actin-depolymerization, 
thereby promoting F-actin accumulation.59, 67 RhoA signalling pathways are displayed in 
Figure 15. 
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Figure 15  RhoA signalling. RhoA is active at the sides and the rear of the cell where it induces the 
formation of stress fibres, leading to cell contraction. 
 
In summary, Rho GTPases are essential for the remodelling of the actin cytoskeleton and, 
thus, for cell migration. Rac1 and Cdc42 are active at the cell front, where they promote the 
extension of lamellipodia and filopodia, respectively. RhoA is active at the sides and the rear 
of the cell, associated with stress fibre formation and cell body contraction. RhoA and Rac1 
are mutually antagonistic, each suppressing the others activity.74 
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2.6.4 Focal adhesion kinase (FAK) 
FAK plays a crucial role in cell migration. It gets activated by numerous stimuli like integrins 
and growth factors and serves as a receptor-proximal regulator of cell motility. At focal 
adhesions, it functions as an adapter protein to recruit other adhesion proteins to their 
regulators, affecting the assembly and disassembly of focal adhesions. FAK activity and 
downstream-signalling affects cell-cell (cadherin-based) contacts and it is implicated in the 
regulation of microtubule structures and the actin cytoskeleton during cell migration. Thus, 
FAK can influence the activity of Rho GTPases via direct interaction with or phosphorylation 
of activators or inhibitors of Rho GTPases (Figure 16).  
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Figure 16  The role of FAK in cell migration. FAK gets activated by integrin clustering or growth 
factors, respectively. It influences cell migration by regulating focal adhesion turnover at the leading edge and 
the trailing edge of migrating cells. Furthermore, it regulates cell-cell adhesions, and it controls the organization 
of the cytoskeleton via Rho GTPases. 
 
The activation of FAK is dependent on phosphorylation of tyrosine residues. FAK possesses 
six tyrosine residues that are phosphorylated by various agonists, transmitting different 
signals and effects. Tyr397 is an autophosphorylation site required for the catalytic activity of 
FAK.75 Phosphorylation at Tyr397 recruites and activates Src homology-2 (SH2) domain-
containing proteins, including members of the Src family kinases. These phosphorylate FAK 
at tyrosines Tyr576, Tyr577, and Tyr821 which is important for the maximal activation of 
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FAK and its signalling to downstream effectors.75, 76 Phosphorylation of FAK at Tyr925 is 
important for the recruitment of other adapter proteins. 
FAK also can get phosphorylated on serine residues, i.e. on Ser722, Ser732, Ser843, and 
Ser910.75 The role of serine phosphorylation of FAK is poorly understood. In neurons, it has 
been shown that Cdk5 phosphorylates FAK at Ser732, which regulates microtubule 
organization, nuclear movement and neuronal migration, but not the catalytic acivity of 
FAK.35 Another work illustrates that the phosphorylation of FAK at Ser732 is induced by 
RhoA-dependent kinase ROCK and is essential for the phosphorylation of FAK at Tyr407, 
promoting cell migration.76 Phosphorylation sites of FAK are displayed in Figure 17. 
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Figure 17  Phosphorylation sites of FAK. FAT: Focal adhesion targeting region, FERM: Protein four.1, 
ezrin, radixin, moesin domain (interacts with integrins and growth factor receptors), FRNK FAK-related-non-
kinase domain (c-terminal non catalytic domain). 
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3 MATERIALS AND METHODS 
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3.1 Materials 
3.1.1 Roscovitine and its derivatives LGR561, LGR848, and LGR849 
“Roscovitine” refers to (R)-roscovitine, as the (R)-stereoisomer was used. Roscovitine was 
from Sigma Aldrich, Munich, Germany. The LGR compounds were kindly provided by V. 
Krystof from Palacky University & Institute of Experimental Botany, Czech Republic.  
All compounds were dissolved in DMSO at 100 mM. 10 µl aliquots were stored at -20°C for 
long time storage, and at 4°C for direct laboratory use. 
For experiments, the compounds were freshly diluted in growth medium to 100 µM and 
further diluted to the indicated concentrations (10 µM and 30 µM, respectively). 
3.1.2 Biochemicals and inhibitors 
Biochemicals 
bFGF       PeproTech, Rocky Hill, NY, USA 
VEGF       PeproTech, Rocky Hill, NY, USA 
 
Inhibitors 
CompleteTM      Roche, Mannheim, Germany 
Na3VO4      ICN Biomedicals, Aurora, Ohio, USA 
NaF       Merck, Darmstadt, Germany 
Phenylmethylsulfonylfluorid (PMSF) Sigma Aldrich, Munich, Germany 
Y27632     Sigma Aldrich, Munich, Germany 
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3.2 Cell Culture  
3.2.1 Solutions and reagents 
The following solutions and reagents were used for the isolation as well as for the cultivation 
of endothelial cells. 
 
PBS (pH 7,4) 
NaCl    123.2  mM 
Na2HPO4   10.4  mM 
KH2PO4   3.2  mM 
H2O 
 
 
 
 
PBS+Ca2+/Mg2+ (pH 7,4) 
NaCl    137  mM 
KCl    2.68  mM 
Na2HPO4   8.10  mM 
KH2PO4   1.47  mM 
MgCl2   0.25  mM 
CaCl2    0.5  mM 
H2O 
 
Trypsin/EDTA (T/E) 
Trypsin   0.05  % 
EDTA   0.20  % 
PBS 
 
Growth medium 
ECGM   500  ml 
Supplement   23.5  ml 
FCS    50  ml 
Antibiotics   3.5  ml 
 
Collagen A  
Collagen A   10  % 
PBS  
 
 
Freezing medium 
FCS    50  % 
DMSO   8  % 
ECGM 
 
Stopping medium 
M 199   500  ml 
FCS    50  ml 
 
 
 
Collagen G 
Collagen G   0.001  % 
PBS 
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Cell culture reagents 
Collagen A       BIOCHROME AG, Berlin, Germany 
Collagen G       BIOCHROME AG, Berlin, Germany 
Collagenase A      Roche, Mannheim, Germany 
Culture flasks, plates, dishes     TPP, Trasadingen, Switzerland 
ECGM containing supplement and antibiotics  Provitro, Berlin, Germany 
FCS       PAA, Pasching, Austria 
ibidi slides       ibidi GmbH, Munich, Germany 
M199        PAN Biotech, Aidenbach, Germany 
 
Foetal Calf Serum (FCS) 
FCS “Gold” was tested for mycoplasm and endotoxin. For heat inactivation, FCS was 
partially thawed for 30 min at room temperature. Subsequently, it was totally thawed at 37°C 
using a water bath. Finally, FCS was inactivated at 56°C for 30 min. Thereafter, 50 ml 
aliquots of heat inactivated FCS were stored at -20°C. 
 
3.2.2 Endothelial cells 
Endothelial cells (ECs) were cultured under constant humidity at 37°C and with 5% CO2 in an 
incubator (Heraeus, Hanau, Germany). Cells were routinely tested for contamination with 
mycoplasm using the PCR detection kit VenorGeM (Minerva Biolabs, Berlin, Germany). 
 
HMEC-1 – Human microvascular endothelial cells 
The cell line CDC/EU.HMEC-1 was kindly provided by Centers for Desease Control and 
Prevention (Atlanta, GA, USA). The immortalized HMEC-1 cell line was created by 
transfection of human dermal microvascular endothelial cells with a plasmid coding for the 
transforming SV40 large T-antigen. HMEC-1 were shown to retain endothelial morphologic, 
phenotypic, and functional characteristics.77, 78 HMECs were used for cell cycle analysis. 
 
HUVEC – Human umbilical vein endothelial cells 
Human umbilical cords were kindly provided by Klinikum München Pasing, Frauenklinik Dr. 
Wilhelm Krüsmann, and Rotkreuzklinikum München. After childbirth, umbilical cords were 
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placed in PBS+Ca2+/Mg2+ containing Penicillin (100 U/ml) and Streptomycin (100 µg/ml), 
and stored at 4°C. Cells were isolated in the space of 1 week. The umbilical vein was washed 
with PBS+Ca2+/Mg2+, filled with 0.1 g/l collagenase A, and incubated for 45 min. at 37°C. To 
isolate endothelial cells, the vein was flushed with stopping medium and the eluate was 
centrifuged (1000 rpm, 5 min.). Afterwards, cells were resolved in growth medium and plated 
in a 25 cm2 flask. After reaching confluency, cells were trypsinized and plated in a 75 cm2 
flask. Experiments were performed using cells at passage 3. HUVECs were used for all assays 
except cell cycle analysis. 
 
3.2.3 Passaging 
After reaching confluency, cells were either sub-cultured 1:3 in 75 cm2 culture flasks or 
seeded either in multiwell-plates or dishes for experiments. For passaging, medium was 
removed and cells were washed twice with PBS before incubation with trypsin/ethylene 
diamine tetraacetic acid (EDTA) (T/E) for 1-2 min at 37°C. Thereafter, cells were gradually 
detached and the digestion was stopped using stopping medium. After centrifugation (1,000 
rpm, 5 min, 20°C), the pellet was resuspended in growth medium and cells were plated. 
 
3.2.4 Freezing and thawing 
For freezing, confluent HMECs from a 75 cm² flask were trypsinized, centrifuged (1,000 rpm, 
5 min, 20°C) and resuspended in 3 ml ice-cold freezing medium. 1.5 ml aliquots were frozen 
in cryovials. After storage at -80°C for 24 h, aliquots were moved to liquid nitrogen for long 
term storage. 
For thawing, a cryovial was warmed to 37°C and the content was immediately dissolved in 
prewarmed growth medium. In order to remove DMSO, cells were centrifuged, resuspended 
in growth medium and transferred to a 75 cm² culture flask. 
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3.3 Angiogenesis assays 
3.3.1 Proliferation assay (crystal violet staining assay) 
The crystal violet staining assay was used to determine effects of the different compounds on 
endothelial cell proliferation. 
1.5 x 103 cells in 100 µl growth medium were seeded into 96 well plates. After 24 h, cells in a 
reference plate were stained with crystal violet, serving as initial cell number. For stimulation, 
100 µl growth medium containing the indicated compounds were added. After 72 h, the 
medium was removed and cells were stained with 100 µl of the crystal violet solution for 10 
min. at room temperature. After washing five times with distilled water, the bound dye was 
solubilized by adding 100 µl of the dissolving buffer. The absorbance was measured at  
540 nm in a plate-reading photometer (SPECTRAFluor Plus; Tecan, Crailsheim, Germany). 
 
Crystal violet solution Dissolving buffer 
 
Crystal violet    0.5  % Sodium citrate 0.1 M   50  % 
Methanol    20  % Ethanol    50  % 
H2O  
  
3.3.2 CellTiter-Blue® Cell Viability Assay 
The CellTiter-Blue® Cell Viability Assay (CTB assay, Promega Corporation, Madison, WI, 
USA) is a method to determine the viability of cells. It uses the indicator dye resazurin to 
measure the metabolic capacity of cells which is considered as an indicator of viability 
(Figure 18).  
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Figure 18  CTB assay. Reduction of resazurin to resarufin by metabolically active cells results in the 
generation of a fluorescent product.  
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The CTB assay was used to determine possible cytotoxic effects of Cdk5 siRNA.  
Transfected cells were seeded into 96 Well plates (20,000 cells per well in 100 µl growth 
medium). After 24 or 48 h, 20 µl of the CellTiter-Blue Reagent® was added and cells were 
incubated for 1 h in an incubator. Afterwards, fluorescence was measured at 560 nm. 
 
3.3.3 Scratch assay 
Using the scratch assay, also called wound healing assay, the migration of cells was analyzed. 
 
Experiments with the Cdk inhibitors: 
HUVECs were seeded in a 24 well plate. After reaching confluency, cells were scratched 
using a pipette tip of a micropipette. The wounded monolayers were washed twice with 
PBS+Ca2+/Mg2+ to remove floating cellular debris before adding growth medium containing 
roscovitine (10 µM and 30 µM) or LGR561, LGR848, or LGR849 (10 µM), respectively. 
 
siRNA experiments: 
Immediately after transfection with the respective siRNAs, HUVECs (500,000/well) were 
plated in a 24 well plate. 32 h after transfection, cells were scratched, washed twice with 
PBS+Ca2+/Mg2+ and treated with growth medium. 
 
After 16 h of migration, cells were washed with PBS+Ca2+/Mg2+, fixed with 3% 
formaldehyde and images were taken using the TILLvisON system (TILL Photonics GmbH, 
Gräfelfing, Germany) and a CCD-camera connected to an Axiovert 200 microscope (Zeiss, 
Oberkochen, Germany). Images were analyzed using specific software (S.CO LifeScience, 
Garching, Germany). Migration was quantified as the ratio of the number of pixels in the area 
covered with cells (yellow) and the number of pixels in the cell-free area (gray) (Figure 19). 
 
 
 
Figure 19  Scratch assay. Images represent cells after 16 h of migration treated with growth medium (left 
panel) or with serum-free medium (M199) (right picture).  
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3.3.4 Chemotaxis assay 
The chemotaxis assay is a tool for observing chemotactical responses of adherent migrating 
cells over extended periods of time.  
 
Seeding of cells and generation of the FCS gradient 
6 µl of cell suspension containing 5x106 HUVECs per ml was added into the observation 
channel of a special µ-slide for chemotaxis (ibitreat, chemotaxis, ibidi GmbH, Munich, 
Germany) and the slide was incubated until cells attached (4 h). To generate the FCS gradient, 
the chambers of the chemotaxis slide were completely filled with serum-free medium (M 199) 
Afterwards, growth medium containing 30 % FCS was added into one chamber. Accordingly 
to the manufacturers protocol, after a short time, the chemoattractant diffuses through the 
observation area and establishes a linear concentration profile from 0% FCS to 10% FCS over 
the cells. For stimulation, roscovitine (10 µM and 30 µM, respectively) was added to both 
media. The chemotaxis chamber is displayed in Figure 20. 
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Figure 20  Chemotaxis chamber. Two large volume chambers are connected by a thin slit (observation 
channel). The reservoirs contain different chemoattractant (FCS) concentrations (blue: 0 % FCS; red: 30 % 
FCS). Inside the observation channel, a linear and stable concentration profile is generated by diffusion of the 
chemoattractant (0 % - 10 % FCS).  
 
Life cell imaging: 
Immediately after gradient formation, life cell imaging was performed using a Zeiss LSM 510 
META confocal microscope equipped with a heating stage from EMBLem (Heidelberg, 
Germany). During observation, cells were incubated with constant humidity at 37°C and with 
5% CO2. Images of cells were obtained every 10 min. for 24h.  
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Cell tracking and evaluation: 
Cells were tracked using the Manual Tracking plug-in by Fabrice P. Cordelieres 
(http://rsb.info.nih.gov/ij/plugins/manual-tracking.html). After tracking, movies were 
evaluated using the Chemotaxis and Migration Tool (Version 1.01) (ibidi GmbH, Munich, 
Germany) for ImageJ (http://rsb.info.nih.gov/ij/). For statistical analysis, Euclidean distance 
(direct cell path) and Cumulative distance (complete cell path) were calculated (Figure 21). 
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Figure 21  Euclidean and Cumulative distances. An intact Cumulative distance together with a reduced 
Euclidean distance refers to a loss of cell orientation. The shortening of both distances indicates a loss of cell 
motility. 
 
3.3.5 Tube formation assay 
Using tube formation assays, the ability of endothelial cells to form three-dimensional 
capillary-like structures was analyzed. BD Matrigel® Matrix Growth Factor Reduced (GFR) 
(BD Biosciences, Heidelberg, Germany) was used as extracellular matrix (ECM). Matrigel® 
Matrix is a solubilised basement membrane preparation extracted from EHS mouse sarcoma.  
The Matrigel® Matrix was thawed at 4°C overnight and kept on ice until use. Ibidi 
angiogenesis-slides (18-well, ibidi GmbH, Munich, Germany) were coated with the Matrigel® 
Matrix (19 µl per well) using precooled pipette tips. For polymerization of the Matrigel® 
Matrix, the slides were incubated at 37°C for 30 min. Afterwards, the gels were overlaid with 
30 μl growth medium containing 1x104 HUVECs and the respective compounds in the 
indicated concentrations. Cells were incubated for 16 h and images were taken using the 
TILLvisON system. Evaluation of pictures was performed by S. CO LifeScience (Garching, 
Germany). For quantification, two parameters were analyzed according to Figure 22: tube 
length (red) and number of nodes (blue crosses in yellow areas). 
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Figure 22  Tube formation assay. Images represent cells cultured onto Matrigel® for 16 h and treated 
with growth medium (left panel) or growth medium containing roscovitine (30 µM, right picture). 
 
3.3.6 Mouse aortic ring assay 
Mouse aortic rings were kindly prepared by PD Dr. Stefan Zahler and Bianca Hager (both 
Ludwig-Maximilians-University of Munich, Department of Pharmacy – Centre of Drug 
Research). After preparation, mouse aortic rings were embedded into BD Matrigel® Matrix 
Growth Factor Reduced (GFR) (BD Biosciences, Heidelberg, Germany), overlaid with 
growth medium and incubated with constant humidity at 37°C and with 5% CO2. Once 
endothelial cell sprouting occurred (about 3 to 5 days), the growth medium was removed, and 
rings were either treated with growth medium or with growth medium containing the different 
compounds in the indicated concentrations. After further incubation for 72 h, images were 
taken using the TILLvisON system. The experimental procedure of the mouse aortic ring 
assay is displayed in Figure 23. 
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Figure 23  Mouse aortic ring assay. After preparation, mouse aortic rings were embedded into Matrigel® 
Matrix. Once endothelial cells started to sprout, rings were stimulated with the indicated compounds. After 
another 3 days, images were taken.  
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3.3.7 Chick chorioallantoic membrane (CAM) assay  
The CAM assay currently is one of the most widely used in vivo models for the study of anti-
angiogenic agents due to its technical simplicity and low cost.79  
 
Preparation of cellulose disks: 
After mixing the contents of the cellulose solution, the mixture was autoclaved, resulting in a 
homogenized, clear solution. For each disk, 200 µl of the warm solution were given into the 
preformed circles of the lid of a 96 well plate. For polymerization, the solution was dryed 
under a laminar air flow for 48 h. Afterwards, the cellulose disks were removed using 
tweezers.  
 
Cellulose solution 
HEC (Hydroxyethyl-Cellulose)    2.5   % 
PVP 17 (Polyvinylpyrrolidone)    2   % 
PEG 400 (Polyethylenglycole)    2   % 
H2O 
 
Preparation and stimulation of the eggs: 
Fertilized White Leghorn chicken eggs (Lohmann Tierzucht, Cuxhaven, Germany) were 
incubated at 37°C for 72 h with constant humidity. Afterwards, the eggs were cleaned with 
70% ethanol, opened, and each egg was transferred into a 100 mm culture dish (whole 
embryo culture). During the following incubation for 72 h the embryo grew and the CAM 
developed over the yolk sac. At that time, the eggs were stimulated using the cellulose disks. 
Four cellulose disks were placed onto each egg, localized on similar sites of the CAM. 
Subsequently, VEGF (1 ng per disk) or VEGF and the indicated compounds (45 µg of the 
compound per disk) were placed directly onto the cellulose disks. Cellulose disks without any 
stimulus were used to verify that the procedure itself causes no vascularization. The next day, 
the vascular structure in the CAM was visualized using a stereomicroscope and a CCD 
camera (Olympus, Munich, Germany). The experimental procedure of the CAM assay is 
displayed in Figure 24. 
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Figure 24  CAM-assay. Eggs were incubated for three days, opened, and stimulated after another three 
days with VEGF or with VEGF and the indicated compounds using the cellulose disks. The respective stimulus 
was directly given onto a cellulose disk. Four cellulose disks were given onto each egg. 24 h after stimulation, 
images were taken. 
 
3.3.8 Mouse cornea micropocket angiogenesis assay 
The mouse cornea micropocket angiogenesis assay uses the avascular cornea as a canvas to 
study angiogenesis in vivo. By the use of standardized slow-release pellets containing basic 
fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF), over the 
course of 5 days a predictable angiogenic response is generated and can be quantified.80 
 
The mouse cornea micropocket assay was kindly performed by Prof. Dr. György Vereb 
(Medical and Health Science Center, Department of Biophysics and Cell Biology, University 
of Debrecen, Hungary) and by Dr. Lili Takács (Medical and Health Science Centre, 
Department of Ophthalmology, University of Debrecen, Hungary). 
Both eyes of C57BL/6J 8-week old female mice (20-21 g body-weight) were implanted with 
pellets containing bFGF as described previously.81, 82 
 
Pellet preparation: 
A solution of 20 µg bFGF (R&D Systems) in 40 µl PBS was mixed with 10 mg sucralfate 
(Sucrose octasulfate-aluminium complex, Sigma Aldrich, Munich, Germany) and lyophilized. 
The lyophilisate was resuspended using 10 μl of 12% Hydron (Poly (2-hydroxyethyl-
methacrylate), Sigma Aldrich, Munich, Germany) in 70% ethanol. This mixture was evenly 
spread into a 16x16-hole area of a Sefar PEEKtex open mesh precision fabric V17-300/36 
(kindly provided by Dr. Thomas Wechsler, Sefar AG, Switzerland). Both sides of the mesh 
were covered with a solution of 12% Hydron in 90% ethanol. After complete drying (1 h), the 
fibres of the mesh were pulled apart and the size and shape of each pellet were examined. 
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Only pellets with proper height and square shape (0.3x0.3x0.2 mm) were used. The final 
bFGF content was 80 ng bFGF per pellet. 
 
Pellet implantation: 
Mice were anesthetized with 10 μl/g body weight pentobarbital. Polyvidon iodide eyedrop 
was used as local disinfectant, and tetracaine for local anesthesia of the cornea. Under a stereo 
microscope (Zeiss), a central vertical cut was made to mid-thickness of the cornea. Starting 
from this, a nasal pocket in the corneal tissue was generated using a modified von Graefe’s 
knife, ending about 1.2 mm from the limbus. The pellet was slipped into the pocket and the 
edge of the wound was smoothed back. Tobramycine eye ointment was used to protect from 
immediate superinfection (Figure 25). 
 
 
Figure 25  Creation of a corneal micropocket and pellet implantation. The image is adapted from 
Rogers et al.80 
 
Drug administration: 
Mice were daily injected with either DMSO (control) or with the indicated compounds for 5 
days, starting at the time of operation. Roscovitine was dissolved in DMSO at 100 mg/ml and 
diluted with sterile PBS to 10 mg/ml. For complete dissolving, HCl had to be added to a final 
concentration of 20 mM. The LGRs were dissolved in DMSO at 70 mg/ml and diluted with 
sterile PBS to 3 mg/ml. For complete dissolving of LGR561, HCl had to be added to a final 
concentration of 10 mM. For each application, 200 µl of the solutions were injected intra-
peritoneally. For each time, mice received 100mg/kg body weight of roscovitine or 30 mg/kg 
body weight of the LGR compounds, respectively. 
 
Quantification of the neovascularization: 
On postoperative day 6, vascularization was quantified under a stereo microcope, using a 
custom made calibrated ocular scale. Vessel length (VL) was defined as the length of the 
longest vessel emanating from the limbus towards the pellet. Clock hours (CH) were defined 
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as the fraction of limbal circumference giving rise to vessels in 1/12th units of the whole 
perimeter. Vascularized area was calculated as 1/2π x VL x 0.4CH, approximating the shape 
to a half ellipse, and taking the perimeter of the cornea as 9.6 mm. Eyes with inflammation, 
destroyed pellet (possibly owed to scratching by the animal), or operation error were omitted 
from the analysis. Pellets without bFGF but in every other respect identically created and 
implanted were used to verify that the procedure itself causes no vascularization. 
Vascularized area (VA):
VA = 1/2π x VL x 0.4CH
a b c d
 
Figure 26  Assessment of corneal neovascularization. (a) The image displays corneal 
neovascularization. (b) Measurement of vessel length (VL). (c) Analysis of clock hours (CH, right picture) (d) 
Calculation of the Vascularized Area from VL and CH (the formula is displayed in the figure). The image is 
adapted from Rogers et al.80 
 
3.4 Western Blot analysis 
Western blot analysis is an extensively used technique to identify specific proteins in various 
protein mixtures, e.g. cell lysates or tissue homogenates. It includes the electrophoretic 
separation of proteins accordingly to their molecular weights, their transfer to a membrane 
(“blotting”), and their visualization by immunodetection. 
 
3.4.1 Preparation of samples 
Endothelial cells were treated as indicated, washed once with icecold PBS and subsequently 
lyzed in Ripa lysis buffer. Immediately, cells were frozen at -85°C. Afterwards, cells were 
scraped off and transferred to Eppendorf tubes (Peske, Aindling-Arnhofen, Germany) before 
centrifugation (14,000 rpm, 10 min, 4°C). Protein concentration was determined using the 
BCA or the Bradford assay, respectively. Afterwards, Laemmli sample buffer (3x) was added 
and samples were heated at 95°C for 5 min. The reducing agent β-Mercaptoethanol cleaves 
disulfide bonds and boiling leads to complete denaturation of the proteins. SDS is an anionic 
detergent that attaches to hydrophobic parts of the proteins, resulting in permanent negatively 
charged proteins. Samples were kept at -20°C until Western blot analysis. 
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Ripa lysis buffer 
NaCl    150  mM 
Tris    50  mM 
Nonidet P-40   1  % 
Deoxycholat   0.25  % 
SDS    0.10  % 
H2O 
add before use: 
CompleteTM   4  mM 
PMSF    1  mM 
NaF    1  mM 
activated Na2VO3  1  mM 
 
Laemmli sample buffer (3x) 
Tris-HCl   187.5  mM 
SDS    6  % 
Glycerol   30  % 
Bromphenolblue  0.025  % 
H2O 
add before use: 
β-mercaptoethanol  12.5  % 
 
 
 
 
 
3.4.2 SDS-PAGE electrophoresis 
Proteins were separated by discontinuous SDS-polyacrylamid gel electrophoresis (SDS-
PAGE) according to Laemmli.83 Equal amounts of protein were loaded on gels and separated 
using the Mini-PROTEAN 3 electrophoresis module (Bio-Rad, Munich, Germany). 
Discontinuous polyacrylamide gels were used consisting of separation and stacking gel. The 
concentration of RotiophoreseTM Gel 30 (acrylamide) in the separating gel was adjusted for an 
optimal separation of the proteins depending on their molecular weights (Table 2). 
Electrophoresis was carried out at 100 V for 21 min for protein stacking and 200 V for 45 min 
for protein separation. The molecular weight of proteins was determined by comparison with 
the prestained protein ladder (PageRulerTM, Fermentas, St. Leon-Rot, Germany). 
 
Table 2   Acrylamide concentration in the separation gel 
 
Protein        acrylamide concentration  
Cdk2, Cdk5, ERK, p27kip1, 
RhoA, Rac1        15  % 
β-tubulin, AKT       12  % 
FAK         10  % 
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Separation gel 10/12/15 % 
RotiphoreseTM Gel 30  33.3/40/50 
     % 
Tris (pH 8.8)    375  mM  
SDS     0.1  % 
TEMED    0.1  % 
APS     0.05  % 
H2O 
 
Electrophoresis buffer 
Tris     4.9  mM 
Glycine    38  mM 
SDS     0.1  % 
H2O 
Stacking gel 
RotiphoreseTM Gel 30  40  % 
Tris (pH 6.8)    125  mM 
SDS     0.1  % 
TEMED    0.2  % 
APS     0.1  % 
H2O 
 
 
 
 
 
 
 
 
3.4.3 Electroblotting 
After protein separation, proteins were transferred onto either PVDF or nitrocellulose 
membranes by electroblotting. Electroblotting, also denoted as Western blotting, is the most 
commonly used method to transfer proteins from a gel to a membrane.84 The protein transfer 
can be achieved either by placing the gel-membrane sandwich between absorbent paper 
soaked in transfer buffer (semi-dry transfer) or by complete immersion of the gel-membrane 
sandwich in a buffer (wet transfer). In the present work semi-dry transfer has been used. 
 
Semi-dry transfer: 
Using a Transblot SD semidry transfer cell (Bio-Rad, Hercules, USA), the separated proteins 
were electrophoretically transferred to a PVDF membrane (Immobilon-P, Millipore, Bedford, 
MA, USA) or to a nitrocellulose membrane (Hybond ECl, Amersham Biosciences, NJ, USA). 
Prior to blotting, the membrane was incubated for at least 30 min in Anode buffer on a 
shaking platform. For semi-dry transfer, the gel-membrane sandwich is placed between 
carbon plate electrodes. Therefore, one sheet of thick blotting paper (Whatman Schleicher & 
Schüll, Dassel, Germany) was soaked with Anode buffer and rolled onto the anode. 
Subsequently, the membrane and the gels were added. Finally the stack was covered with 
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another sheet of thick blotting paper soaked with Cathode buffer. The transfer cell was closed 
and transfer was carried out at 15 V for 1 h. 
 
Anode buffer 
Tris     12  mM 
CAPS     8  mM 
Methanol    15  % 
H2O 
 
Cathode buffer 
Tris     12  mM 
CAPS     8  mM 
SDS     0.1  % 
H2O  
 
3.4.4 Protein detection 
3.4.4.1 Specific protein staining with antibodies 
Prior to the immunological detection of the relevant proteins, unspecific protein binding sites 
were blocked. Therefore, the membrane was incubated in Blotto 5% or BSA 5% for 2 h at 
room temperature. Afterwards, detection of the proteins was performed by incubating the 
membrane with the respective primary antibody at 4°C overnight. After four washing steps 
(each 5 min.) with PBS containing 0.1% Tween (PBS-T), the membrane was incubated with 
the secondary antibody, followed by 4 additional washing steps. All steps regarding the 
incubation of the membrane were performed under gentle agitation. 
In order to visualize the proteins, two different methods have been used depending on the 
labels of secondary antibodies. 
 
Antibodies directly labeled with infrared (IR) fluorophores: 
Secondary antibodies coupled to IRDyeTM800 and Alexa Fluor® 680 with emission at 800 and 
700 nm, respectively, were used. Membranes were incubated for 1 h. Protein bands of interest 
were detected using the Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE). After 
scanning the membrane with two-color detection, bands could be quantified using Odyssey 
software. 
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Antibodies coupled to horseradish peroxidase (HRP) 
Membranes were incubated for 2 h with HRP-conjugated secondary antibodies. For detection, 
luminol was used as a substrate. The membrane was incubated in a 1:0.025 mixture of ECL 
solution A and B for 1 minute (ECL Plus Western Blotting Detection Reagent RPN 2132, GE 
Healthcare, Munich, Germany). The enzyme HRP catalyzes the oxidation of luminol in the 
presence of H2O2 (Figure 27). The appearing luminescence was detected by exposure of the 
membrane to an X-ray film (Super RX, Fuji, Düsseldorf, Germany) and subsequently 
developed with a Curix 60 Developing system (Agfa-Gevaert AG, Cologne, Germany).  
 
 
 
 
Figure 27  HRP-Luminol reaction 
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Primary antibodies used for protein detection are listed in Table 3; secondary antibodies are 
displayed in Table 4. 
 
Table 3   Primary antibodies. 
 
Antigen  Isotype  Dilution  in   Provider 
Actin   mouse monoclonal 1:1,000 Blotto 1 % Chemicon 
AKT   rabbit polyclonal 1:1,000 Blotto 1 % Cell Signaling 
AKT phospho  mouse monoclonal 1:1,000 Blotto 1 % Cell Signaling 
β-tubulin  mouse monoclonal 1:500  Blotto 1 % Santa Cruz 
Cdk2   rabbit polyclonal 1:1,000 Blotto 1 % Santa Cruz 
Cdk5   mouse monoclonal 1:1,000 Blotto 1 % Santa Cruz 
ERK   rabbit polyclonal 1:1,000 Blotto 1 % Cell Signaling 
ERK phospho  mouse monoclonal 1:1,000 Blotto 1 % Cell Signaling 
FAK   mouse monoclonal 1:1,000 BSA 1 % Santa Cruz 
FAK phosphoSer732 rabbit polyclonal 1:1,000 BSA 1 % Biosource 
FAK phosphoTyr397 rabbit polyclonal 1:1,000 BSA 1 % Santa Cruz 
p27kip1   mouse monoclonal 1:1,000 Blotto 1 % Biosource 
Rac1   mouse monoclonal 1:1,000 Blotto 3 % Upstate 
RhoA   mouse monoclonal 1:250  Blotto 5 % Upstate 
 
Table 4   Secondary antibodies. 
 
Antibody     Dilution  in   Provider 
Goat anti-mouse IgG1: HRP    1:1,000  Blotto 1%  Biozol 
Goat anti mouse IgG2b: HRP  1:1,000 Blotto 1% Southern 
          Biotechnology 
Goat anti-rabbit: HRP    1:1,000  Blotto 1%  Dianova 
Alexa Fluor® 680 Goat anti-mouse IgG  1:10,000  Blotto 1%  Molecular Probes 
Alexa Fluor® 680 Goat anti-rabbit IgG  1:10,000  Blotto 1%  Molecular Probes 
IRDyeTM 800 Goat anti-rabbit IgG   1:10,000  Blotto 1%  Rockland 
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3.4.4.2 Unspecific protein staining of gels and membranes 
In order to ensure equal protein loading and blotting efficiency, gels as well as membranes 
were stained with Coomassie or Ponceau staining solution, respectively. 
 
Staining of gels with Commassie staining solution: 
After transfer, gels were incubated with Coomassie staining solution for 20 min. The dye 
penetrates the gel and stains all proteins without any specification. Afterwards, gels were 
extensively washed with Coomassie destaining solution for 60 min (6x, 10 min) until proteins 
appeared as blue bands. 
 
Coomassie staining solution 
Coomassie blue G   0.3  % 
Glacial acetic acid   10  % 
Ethanol    45  % 
H2O 
 
Coomassie destaining solution 
Glacial acetic acid   10  % 
Ethanol    33  % 
H2O 
 
 
Staining of membranes with Ponceau solution: 
Membranes were incubated with Ponceau solution on a shaking platform for 5 min and were 
washed with water until the background disappeared. 
 
Ponceau solution 
Ponceau S    0.1  % 
Glacial acetic acid   5  % 
H2O 
 
 
 
 
3.4.5 Membrane stripping and reprobing 
In order to remove primary and secondary antibodies from the membrane (“stripping”), blots 
were incubated twice in stripping buffer for 15 min at room temperature. After extensive 
washing, stripping efficiency was confirmed by scanning the membrane to see if signals have 
been removed. Subsequently, the blot was re-blocked with Blotto 5% for 2 h and incubated 
with antibodies. 
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Stripping buffer (pH 2.0) 
Glycine    25  mM 
SDS     0.1  % 
H2O 
 
 
 
 
 
3.5 Protein quantification  
In order to employ equal amounts of proteins in all samples for Western Blot analysis, protein 
concentrations were determined using either Bicinchoninic Protein Assay or Bradford Assay. 
After measurement, protein concentration was adjusted by adding Laemmli sample buffer 
(1x).  
 
3.5.1 Bicinchoninic (BCA) Protein Assay  
Bicinchoninic (BCA) Protein Assay (BC Assay reagents, Interdim, Montulocon, France) was 
performed as described previously.85 10 μl protein samples were incubated with 200 μl BC 
Assay reagent for 30 min at 37°C. Absorbance of the blue complex was measured 
photometrically at 550 nm (Tecan Sunrise Absorbance reader, TECAN, Crailsheim, 
Germany). Protein standards were obtained by diluting a stock solution of Bovine Serum 
Albumin (BSA, 2 mg/ml). Linear regression was used to determine the actual protein 
concentration of each sample. 
 
3.5.2 Bradford Assay 
Bradford Assay (Bradford solution, Bio-Rad, Munich, Germany) was performed as described 
previously.86 It employes Coomassie Brillant Blue as a dye, which binds to proteins. 10 μl 
protein samples were incubated with 190 μl Bradford solution (1:5 dilution in water) for 5 
min. Thereafter, absorbance was measured photometrically at 592 nm (Tecan Sunrise 
Absorbance reader, TECAN, Crailsheim, Germany). Protein standards were achieved as 
described above (BCA Assay). 
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3.6 Transfection of cells 
Transfection refers to the introduction of genetic material into cultured mammalian cells. 
Genetic material (i.e. plasmid DNA or siRNA constructs) can be transfected using calcium 
phosphate, electroporation, lipofection or magnetofection.  
 
For transient transfection with the indicated siRNAs or plasmids, respectively, HUVECs were 
electroporated using the Nucleofector® II device in combination with the HUVEC 
Nucleofector®Kit (both from Amaxa, Cologne, Germany). 
 
Transfection with siRNA 
In order to silence Cdk2 or Cdk5, respectively, HUVECs were transiently transfected with 
Cdk2 as well as Cdk5 siRNA. Two On-TARGETplus Individual Duplexes were used for each 
Cdk (Dharmacon, Lafayette, CO, USA). On-Targetplus siCONTROL Non-targeting siRNA 
was used as a control. SiRNAs were suspended in Dharmacon 1x siRNA buffer, aliquoted and 
stored at -80°C. The concentration of siRNA was verified using a NanoDrop (Wilmington, 
DE, USA). 
For each transfection, 2x106 HUVECs were suspended in 100 μl HUVEC Nucleofector 
Solution and added to 3 µg of the respective siRNA:  
 
Cdk2 siRNA:  
1.5 μg siRNA Duplex J-003236-11 (sequence: 5’-PUAUUAGGAUGGUUAAGCUCUU-3’)  
1.5 µg siRNA Duplex J-003236-12 (sequence: 5’-PUCUCCCGUCAACUUGUUUCUU-3’) 
 
Cdk5 siRNA:  
1.5 μg siRNA Duplex J-003239-09 (sequence: 5’-PACAUCGGAUAGGGCUUAUAUU-3’) 
1.5 μg siRNA Duplex J-003239-10 (sequence: 5’-PGAUCUCAUGAGUCUCCCGGUU-3’) 
 
Non-targeting (nt) siRNA (transfection control): 
3.0 µg ON-TARGETplus siCONTROL Non-targeting (nt) siRNA D-001810-01 
(sequence: 5’-UGGUUUACAUGUCGACUAA-3’) 
 
The mixture of cells and siRNA was transferred to an amaxa certified cuvette and transfection 
was performed (program A-034). Immediately after electroporation, 900 μl of prewarmed 
culture medium was added to the cuvette. Afterwards, cells were seeded into 24-well 
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(500,000 cells per well) for scratch assays, in 6-well (500,000 cells per well) plates for 
Western Blot analysis, or into ibidi µ-slides (8-well ibiTreat, ibidi GmbH, Munich, Germany, 
250,000 cells per well) for staining experiments. Scratch assays were performed 32 h after 
transfection for 16 h. Transfection efficiency was checked 24 and 48 h after transfection by 
Western Blot analysis. For staining experiments, cells were scratched 32 h after transfection 
and stained after migration for 16 h. 
 
Transfection with DNA-constructs 
To visualize the indicated proteins, HUVECs were transiently transfected with plasmids for 
eYFP-Rac1, eYFP-vinculin, eGFP-CLIP170, and eGFP-tubulin. eGFP CLIP-170 was kindly 
provided by N. Galjart (Rotterdam, Netherlands), eYFP-vinculin by A. Bershadsky (Rehovot, 
Israel), and eGFP-tubulin by Stefan Linder (Munich, Germany). eYFP-Rac1 was from 
ATCC/Promochem, Wesel, Germany. 
 
For each transfection, 1x106 HUVECs were suspended in 100 μl HUVEC Nucleofector 
Solution and added to 7 µg of the respective plasmid. Electroporation was performed 
analogical to the siRNA experiments. After transfection, cells were seeded into ibidi µ-slides 
(8-well ibiTreat, ibidi GmbH, Munich, Germany, 250,000 cells per well) or in 24 well plates 
(250,000 cells per well). Experiments were performed 48 h after transfection. 
 
3.7 Confocal laser scanning microscopy 
Confocal laser scanning microscopy is an extensively used method in life sciences due to its 
great advantages. The key feature of the confocal microscopy is that it only captures light 
reflected or emitted by a single plane of a specimen. Out of focus light is filtered out so that 
only light coming from in-focus objects can reach the detector. A laser beam scans the 
specimen pixel by pixel and line by line. Afterwards, data are assembled, resulting in an 
image that represents an optical section through the specimen. This results in high-quality 
images with high contrast and maximum resolution, gives information about colocalization of 
signals from different fluorochromes, and allows three-dimensional reconstructions of thick 
specimens.87 
A Zeiss LSM 510 META confocal microscope (Figure 28) equipped with a heating stage 
from EMBLem (Heidelberg, Germany) was used for obtaining images of fixed cells as well as 
for life cell imaging experiments. 
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Figure 28  Beam path in a confocal Laser Scanning Microscope (adapted from Zeiss AG, 87). 
 
3.7.1 Microscopy with fixed cells 
HUVECs were cultured in ibidi µ-slides (8-well ibiTreat, ibidi GmbH, Munich, Germany) 
until reaching confluency. Afterwards, cells were scratched, treated as indicated, and allowed 
to migrate. After 16 h, cells were washed with PBS and fixed with Cytoskelfix Cell fixative 
solution (Cytoskeleton, Denver, CO) containing 0.2% Triton X-100 (Sigma, Taufkirchen, 
Germany) at -20°C for 4 min. After washing with PBS for 10 min, unspecific binding was 
blocked by incubation with 0.2 % bovine serum albumin (BSA) solution for 30 min. 
Afterwards, cells were incubated with the respective primary antibody for 1 h at room 
temperature (Table 5). 
 
Table 5   Primary antibodies used for confocal microscopy. 
 
Antigen  Isotype  Dilution  in   Provider 
Cortactin  rabbit polyclonal 1:100  BSA 0.2 % Cell Signaling 
Rac1   mouse monoclonal 1:100  BSA 0.2 % Upstate 
 
Following three washing steps with PBS, cells were incubated with the respective secondary 
antibodies or with rhodamin/phalloidin for staining of F-actin, respectively, for 30 min. at 
room temperature (Table 6). 
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Table 6   Secondary antibodies / dye used for confocal microscopy. 
 
Antibody/Dye    Dilution  in   Provider 
AlexaFluor488 goat-anti-mouse  1:400  BSA 0.2 % Molecular Probes 
AlexaFluor546 goat-anti-rabbit  1:400  BSA 0.2 % Molecular Probes 
Rhodamin/phalloidine    1:400  BSA 0.2 % Molecular Probes 
 
Finally, preparates were again washed three times with PBS (5 min) and embedded in 
FluorSave aqueous mounting medium (VWR, Darmstadt, Germany). 
 
3.7.2 Life cell imaging 
Life cell imaging was performed to visualize the dynamics of single cells during migration 
and spreading, as well. 
HUVECs were transfected with 7 µg of the indicated plasmids as displayed in Table 7. 
 
Table 7   Plasmids used for life cell imaging experiments. 
 
Plasmid  visualization of  Provider 
eGFP-CLIP170 microtubule +tips  N. Galjart, Rotterdam, Netherlands 
eGFP-tubulin  microtubules   S. Linder, Munich, Germany 
eYFP-Rac1  Rac1/lamellipodia  ATCC/Promochem, Wesel, Germany 
eYFP-vinculin focal adhesions  A. Bersadsky, Rehovot, Israel  
 
Experiments with migrating cells: 
After transfection with the plasmids as indicated, HUVECs were seeded into ibidi µ-slides (8-
well ibiTreat, 250,000 cells per well). After 48 h, cells were scratched, treated as indicated 
and life cell imaging was performed for 60 min during migration. 
 
Experiments with spreading cells: 
After transfection with the plasmids as indicated, HUVECs were seeded into 24-well-plates 
(250,000 cells per well). After 48 h, cells were trypsinized, resuspended in growth medium 
containing the indicated stimuli, and plated into ibidi µ-slides (8-well ibiTreat). Life cell 
imaging was performed for 60 min during cell spreading. 
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3.7.3 Histological staining 
Human umbilical cords were frozen at -20°C. Cryosections with a size of 20 µm were freshly 
prepared and applied onto glass objective slides. After drying (30 min), sections were 
reconstituted with PBS (10 min) and blocked with 0.2 % BSA in PBS (15 min). Afterwards, 
cells were incubated with the respective primary antibody for 1 h at room temperature  
(Table 8). 
 
Table 8  Primary antibodies used for histological staining. 
 
Antigen  Isotype  Dilution  in   Provider 
Cdk5   mouse monoclonal 1:50  BSA 0.2 % Santa Cruz 
VE cadherin  rabbit polyclonal 1:400  BSA 0.2 % Cell Signaling 
 
Following three washing steps with PBS, cells were incubated with the respective secondary 
antibodies or with bisBenzimide H33342 trihydrochloride for staining of nuclei, respectively, 
for 30 min. at room temperature (Table 9). 
 
Table 9  Secondary antibodies / dye used for confocal microscopy. 
 
Antibody/Dye    Dilution  in   Provider 
AlexaFluor488 goat-anti-mouse  1:400  BSA 0.2 % Molecular Probes 
AlexaFluor546 goat-anti-rabbit  1:400  BSA 0.2 % Molecular Probes 
bisBenzimide H33342 trihydrochloride 1:200  BSA 0.2 % Sigma Aldrich 
 
Finally, preparates were again washed three times with PBS (5 min), embedded in FluorSave 
aqueous mounting medium (VWR, Darmstadt, Germany), and covered with cover slips. 
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3.8 Flow Cytometry (FACS) 
Flow cytometry allows counting, sorting, and analysis of various parameters of single cells or 
particles suspended in a fluid. Each cell passes a focused laser beam and scatters the 
illuminating light. If particles have previously been stained with a fluorescent dye, the same 
time fluorescence emission occurs and can be detected. 
Flow cytometry has been used for the analysis of cell cycle and apoptosis. All measurements 
were performed on a FACSCalibur (Becton Dickinson, Heidelberg, Germany). Cells were 
illuminated by a blue argon laser (488 nm). 
 
Cell cycle analysis and quantification of apoptosis rate 
Cell cycle analysis and quantification of apoptosis rate was performed according to  
Nicoletti et al. 88  
Cells were seeded in 12-well plates and either left untreated or stimulated with roscovitine, 
LGR561, LGR848, or LGR849 in the indicated concentrations. After 48 h, cells were 
trypsinized, washed three-times with PBS, and centrifugated at 600 g and 4°C for 10 min. For 
permeabilization and staining, cells were incubated in hypotonic fluorochrome solution (HFS) 
buffer containing propidium iodide (PI). PI is a red fluorescent dye that intercalates with 
doublestranded DNA, detecting the DNA content of the cell. After incubation at 4°C 
overnight cells were analyzed by flow cytometry. 
 
FACS buffer (pH 7.4) 
NaCl   138.95  mM 
K2HPO4  1.91   mM 
NaH2PO4  16.55   mM 
KCl   3.76   mM 
LiCl   10.14   mM 
NaN3   3.08   mM 
Na2EDTA  0.97   mM 
H2O 
HFS buffer 
Propidium iodide  75  nM 
Sodium citrate  0.1  % 
Triton X-100   0.1  % 
PBS 
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The respective fluorescence intensity gives information about the DNA content of a cell, and 
thus, about rate of apoptosis and cell cycle phases. 
Apoptotic cells are characterized by DNA fragmentation, indicated by a low fluorescence. 
Thus, they appear “left” to the G1/G0 peak in the histogram plot (“sub-G1 peak”) (Figure 29). 
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Figure 29  Analysis of apoptotic cells. In the left panel, untreated cells are displayed. The right panel 
refers to cells treated with LGR561 (100 µM) which show increased rate of apoptosis (sub-G1 peak in the 
histogram plot).  
 
The cell cycle consists of mitosis (M phase) and interphase. The interphase is subdivided into 
G1/G0-phase, S-phase, and G2-phase, characterized by their DNA contents. Cells in G1/G0-
phase exhibit haploid DNA contents (“normal” fluorescence), cells in G2-phase diploid DNA 
contents (“high” fluorescence), and cells in S-phase DNA contents somewhere between. The 
respective fluorescence intensities of cell populations result in characteristic histogram plots 
(Figure 30).  
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Figure 30  Cell cycle analysis. The Histogram plot in the left panel refers to untreated cells (normal 
division of cells in the respective phases). The Histogram plot in the right panel displays cells treated with 
LGR561 (100 µM). They are arrested in the G2-phase of the cell cycle.  
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3.9 Tubulin fractionation 
HUVECs were plated into 6 cm2 dishes. After reaching confluency, cells were either left 
untreated (control) or treated with roscovitine (30 µM), taxol (1 µM), or vinblastine (10 nM), 
respectively. After 4 h, cells were lysed using PIPES lysis buffer. After incubation for 20 min. 
at room temperature, lysates were centrifuged for 45 min with 47,000 rpm (OptimaTM TLX 
Ultracentrifuge, Beckman Coulter, CA, USA). Afterwards, the supernatant containing 
unpolymerized tubulin and the pellet containing polymerized tubulin were separated. The 
supernatant was mixed with Laemmli sample buffer (3x) containing β-mercaptoethanol (1:9) 
and boiled for 5 min. The pellet was incubated with 40 µl CaCl2 buffer at 4°C for 60 min, 
mixed with Laemmli sample buffer (3x) containing β-mercaptoethanol (1:9) and boiled for 5 
min as well. For the detection of β-tubulin, Western Blot analysis was performed. 
 
PIPES lysis buffer (pH 6.9) 
PIPES    100  mM 
Glycerol   2  M 
Triton X-100   0.5  % 
MgCl2   2  mM 
EGTA   2  mM 
H2O 
add before use: 
Taxol    5  µM 
GTP    1  mM 
PMSF    1  mM 
CompleteTM   4  mM 
 
CaCl2 buffer (pH 6.8) 
Tris/HCl   100  mM 
MgCl2   1  mM 
CaCl2    10  mM 
H2O 
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3.10 Pull-down assay 
In a Pull-down assay, the activation state of GTPases can be analyzed. The assay is based on 
the principle that only the active form of the GTPase interacts with its specific downstream 
effectors. The GTPase-binding domains from these downstream effectors are expressed as 
recombinant glutathione S-transferase (GST) fusion proteins immobilized on glutathione resin 
and can be used for affinity precipitation (pull-down) of the active GTPase from cell lysates. 
The N-terminal regulatory region in p21-activated protein kinase 1 and 2 (Pak1 and 2) 
contains the p21-binding domain (PBD) for Rac and Cdc42.9 The N-terminal region of 
Rhotekin contains the Rho-binding domain (RBD).10 Pulled-down active GTPases are eluted 
from the resin and detected by immunoblotting with a specific antibody (Figure 31). 
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Figure 31  Principle of a Pull-down assay. 
 
Pull-down assays were performed using the RhoA Activation Assay Kit 17-294 and 
Rac1/Cdc42 Activation Assay Kit 17-441 (both from Millipore, Billerica, MA, USA). 
HUVECs were trypsinized, suspended in growth medium (control) or growth medium 
containing roscovitine (30 µM) and subsequently plated into two 100 cm2 dishes (about 6 mio 
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cells per sample). After 30 min, cells were lyzed using Mg2+ lysis/wash buffer (MLB, 250 µl 
per dish), scraped off, and transferred to Eppendorf tubes before centrifugation (14,000 rpm, 
10 min, 4°C). For adjustment of protein contents of the respective samples, protein 
concentration was determined using the Bradford-assay. Afterwards, 10 µg of the 
Rac1/Cdc42 assay reagent (PAK1 PBD agarose) or 20 µg of the Rho assay reagent (Rhotekin 
RBD agarose), respectively, were added to 1.0 ml of each lysate. The mixtures were 
incubated at 4°C for 1 h with gentle agitation. After separation of beads and supernatant, the 
supernatant was mixed with Laemmli sample buffer (2x) containing β-Mercaptothanol (1:9) 
and boiled for 5 min at 95°C. The beads were washed three times with 500 µl MLB and 
resuspended in Laemmli sample buffer (2x) containing β-Mercaptothanol (1:9) and boiled for 
5 min at 95°C. For Western Blot analysis, 40 µl of the samples were loaded onto gels. 
 
3.11 Adhesion assay 
24-well plates were either left uncoated or coated with fibronectin (25 µg / ml), Collagen 
(0,001% in PBS) or Matrigel® (10% in serum free medium) for 2 h at 37°C. After washing 
with PBS, the plates were blocked with 0.2 % bovine serum albumin (BSA) solution for 1 h 
and again washed with PBS. 
HUVECs were trypsinized, suspended in ECGM or ECGM containing roscovitine (30 µM), 
and 1x106 cells per well were plated into 24 well plates which were prepared before. After 30 
min., cells were stained with 300 µl crystal violet solution for 10 min. After washing five 
times with distilled water, the bound dye was solubilized by adding 300 µl of the dissolving 
buffer. The absorbance was measured at 540 nm in a plate-reading photometer 
(SPECTRAFluor Plus; Tecan, Crailsheim, Germany). 
 
3.12 Statistical analysis 
All experiments were performed at least three times unless otherwise indicated in the figure 
legend. Data are expressed as mean ± SEM. Statistical analysis was performed with 
SigmaStat software version 3.1 (Aspire Software International). Statistical tests are indicated 
in the figure legend. Statistical significance is assumed if p≤0.05. 
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4 RESULTS 
 
58  RESULTS 
4.1 Roscovitine, LGR561, LGR848, and LGR849 exert anti-angiogenic 
effects in vitro and in vivo 
Angiogenesis involves a cascade of events with the endothelium playing an important role. 
Thus, to elucidate possible anti-angiogenic effects of the Cdk inhibitor roscovitine and its 
derivatives, we analyzed their influence on endothelial cell proliferation, migration and tube 
formation, which represent major steps in the angiogenic cascade. 
 
4.1.1 Roscovitine and the LGRs inhibit endothelial cell proliferation 
The influence of roscovitine and the LGRs on endothelial cell proliferation was analyzed by 
crystal violet staining. All compounds dose-dependently reduced HUVEC proliferation. The 
LGRs, especially LGR561 and LGR849, reduced HUVEC proliferation much more potently 
than roscovitine. The calculated EC50 for each compound is indicated in the respective 
diagram (Figure 32).  
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Figure 32  Roscovitine and the LGRs dose-dependently reduce endothelial cell proliferation. 
HUVECs were either left untreated or treated with the indicated compounds in increasing concentrations. After 
72 h, cell proliferation was determined by staining of cells with crystal violet (Kruskal-Wallis One Way 
ANOVA on Ranks, * p<0.05). EC50 values were calculated using the SigmaStat software. 
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4.1.2 Effects of roscovitine and the LGRs on cell cycle and apoptosis 
In order to understand the mechanism by which the compounds inhibit cell growth, we 
investigated their effects on cell cycle and apoptosis by flow cytometry analyses. The cell 
cycle comprises mitosis (M-phase) and interphase, subdivided into G1/G0-, S-, and G2-phase, 
characterized by the DNA content of the cell. The G1/G0 -phase exhibits the haploid, the G2-
phase the diploid DNA content.  
Treatment of proliferating endothelial cells with increasing concentrations of all compounds 
resulted in a cell cycle arrest in the G2-phase. In detail, roscovitine caused a significant cell 
cycle arrest at a concentration of 100 µM. In comparison, only 10 µM of the two (S)-
stereoisomers LGR561 and LGR849 significantly inhibited cell cycle progression. The (R)-
stereoisomer LGR848 significantly inhibited cell cycle progression at a concentration of 100 
µM (Figure 33). 
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Figure 33  Roscovitine and the LGRs induce cell cycle arrest in G2-phase. Proliferating HUVECs 
were either left untreated or treated with increasing concentrations of roscovitine (Rosc), LGR561, LGR848, and 
LGR849. After 48 h, cells were stained with PI and the DNA content was determined by FACS analysis. (One 
Way ANOVA, Holm-Sidak * p<0.05). 
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Moreover, roscovitine and the LGRs dose-dependently increased apoptosis in proliferating 
endothelial cells (Figure 34). Roscovitine significantly increased apoptosis of HUVECs at a 
concentration of 100 µM, just as well as LGR848. The two S-isomers LGR561 and LGR849 
again were more powerful: they significantly induced apoptosis at a concentration of 10 µM. 
(Figure 34) 
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Figure 34  Roscovitine and the LGRs dose-dependently induce apoptosis in endothelial cells. 
Proliferating HUVECS were either left untreated or treated with increasing concentrations of roscovitine (Rosc), 
LGR561, LGR848, and LGR849 for 48 h. Apoptosis was determined accordingly to the Nicoletti method. (One 
Way ANOVA, Holm-Sidak * p<0.05). 
 
 
RESULTS  61 
4.1.3 Effects of roscovitine and the LGRs on endothelial cell migration 
To analyze the influence of the compounds on the migration of endothelial cells, scratch 
assays were performed. Roscovitine significantly reduced HUVEC migration by 20 % (10 
µM) or 67 % (30 µM), respectively. LGR561 decreased EC migration by 65 % (10 µM), 
LGR849 by 67 % (10 µM). Thus, both inhibited migration much more potently than their 
mother substance roscovitine. LGR848 reduced migration by 21 % at 10 µM, nearly to the 
same extent as roscovitine (Figure 35). 
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Figure 35  Roscovitine and its derivatives inhibit endothelial cell migration. HUVECs were scratched 
and either treated with growth medium (co) or growth medium containing roscovitine (Rosc), LGR561, 
LGR848, or LGR849 in the indicated concentrations for 16 h. Representative images out of three independent 
experiments are shown. The graph displays the ratio of pixels covered by cells and pixels in the wound area. 
(mean ± SEM, Kruskal-Wallis One Way ANOVA on Ranks, * p<0.05 vs control, n=3) 
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4.1.4 Effects of roscovitine on endothelial cell chemotaxis 
To elucidate whether roscovitine abrogates cell migration via inhibiting cell motility per se 
(chemokinesis), or by causing a loss of orientation, migration experiments were performed in 
a chemotactic gradient (chemotaxis assay). Directional migration was induced by a gradient 
towards 10% fetal calf serum (FCS). Cumulative and euclidean distances were measured. 
Untreated cells moved along the FCS gradient (Figure 36 a, upper panel). Cells treated with 
10 µM roscovitine still moved (intact cumulative distance), but did not follow the FCS 
gradient, suggesting a loss of orientation (reduced euclidean distance) (Figure 36 a, middle 
panel). Roscovitine at a concentration of 30 µM reduced both, cumulative and euclidean 
distance, which refers to a completely defective motility (Figure 36 a, lower panel).  
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Figure 36  Roscovitine inhibits chemotaxis in endothelial cells. (a) Representative tracings of untreated 
cells (co, upper panel), cells treated with 10 µM roscovitine (Rosc, middle), and cells treated with 30 µM 
roscovitine (Rosc, lower panel) are displayed. (b) The diagram illustrates cumulative distance (complete cell 
path) and euclidean distance (directional cell path). (c) Quantitative evaluation of cumulative distance and 
euclidean distance is shown (One Way ANOVA/Dunnett, * p<0.05, n=3). 
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4.1.5 Roscovitine and the LGRs inhibit tube formation 
In tube formation assay, the ability of cells to form three-dimensional structures can be 
measured. HUVECs were seeded onto Matrigel® in the absence or presence of roscovitine, 
LGR561, LGR848, and LGR849, respectively. In comparison to untreated cells, tube 
formation of cells treated with roscovitine was reduced dose-dependently (Figure 37). In 
comparison to roscovitine, LGR561, and LGR849 inhibited tube formation more powerfully, 
LGR848 showed a lower activity. For quantitative evaluation, tube length (displayed in red) 
and number of nodes (displayed as blue crosses in yellow areas) were analyzed. 
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Figure 37  Roscovitine, LGR561, LGR848, and LGR849 dose-dependently inhibit tube formation. 
(a) Images show HUVECs seeded onto Matrigel® for 16 h in the absence or presence of the indicated 
compounds. Representative images out of three independent experiments are shown. Tube length is displayed in 
red, the number of nodes is indicated as blue crosses in yellow areas. (b) The graphs represent the quantitative 
evaluation of tube length (left panel, One Way ANOVA/Dunnett, * p<0.05, n=3) and of the number of nodes 
(right panel, One Way ANOVA/Dunn, * p<0.05, n=3). 
 
64  RESULTS 
4.1.6 Roscovitine and the LGRs reduce vessel sprouting out of mouse aortic rings 
Besides endothelial cells, other cell types, such as pericytes or smooth muscle cells, are 
involved in angiogenesis as well.3 Thus, we performed mouse aortic ring assays to test the 
anti-angiogenic properties of roscovitine and its derivatives LGR561, LGR848, and LGR849 
in a more complex model ex vivo. Roscovitine (10 µM and 30 µM) dose-dependently reduced 
vascular sproutings out of aortic rings (Figure 38). LGR561, LGR848, and LGR849 
decreased vessel sprouting at a concentration of 10 µM. 
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Figure 38  Roscovitine, LGR561, LGR848, and LGR849 reduce endothelial cell sprouting out of 
mouse aortic rings. Representative images out of three independent experiments display mouse aortic rings 
embedded into Matrigel® in the absence (co) or presence of roscovitine (Rosc, 10 µM and 30 µM) or its 
derivatives LGR561, LGR848, LGR849 (10 µM), respectively. 
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4.1.7 Roscovitine and the LGRs inhibit vessel formation in the CAM-assay 
Using the chick chorioallantoic membrane (CAM) assay, we analyzed the anti-angiogenic 
properties of the investigated compounds in vivo. We found a strong induction of vessel 
formation by vascular endothelial growth factor (VEGF), which was completely blocked by 
concurrent treatment with roscovitine. LGR561 and LGR849 also strongly reduced VEGF-
induced vessel formation in the CAM. LGR848 exhibited only a slight anti-angiogenic effect 
(Figure 39). 
VEGF
VEGF +  Rosc
VEGF
VEGF +  LGR561
VEGF
VEGF +  LGR848
VEGF
VEGF +  LGR849
 
 
 
Figure 39  Roscovitine, LGR561, and LGR849 abolish VEGF-induced vessel formation in the 
chorioallantoic membrane assay, LGR848 shows only a slight effect. Circles represent localization of 
cellulose disks containing VEGF (1 ng/disk) or VEGF (1 ng/disk) combined with roscovitine (Rosc), LGR561, 
LGR848, or LGR849 (45 µg/disk), respectively. Representative images out of at least three independent 
experiments are shown. 
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4.1.8 Roscovitine and the LGRs reduce neovascularization in the mouse cornea 
micropocket assay 
As an ultimate in vivo proof of principle, the mouse cornea micropocket assay was used to test 
the anti-angiogenic properties of the Cdk inhibitors.  
Vascularization of the per se avascular cornea was induced by the implantation of slow-
release pellets containing bFGF (80 ng per pellet). Intraperitoneally given roscovitine  
(100 mg/kg/day) as well as LGR561, LGR848, and LGR849 (30 mg/kg/day) strongly reduced 
bFGF-induced neovascularization in vivo (Figure 40). 
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Figure 40  Roscovitine, LGR561, LGR848, and LGR849 significantly reduce bFGF-induced 
neovascularization in the mouse cornea micropocket assay. The ingrowth of blood vessels into the pellet 
containing bFGF of one eye of a mouse treated with solvent (DMSO) (co) is shown in the upper left panel. The 
right panel indicates one eye of a mouse injected intraperitoneally with roscovitine (Rosc, 100 mg/kg/day). The 
graph in the lower panel represents the quantitative evaluation of the vascularized area. (One Way 
ANOVA/Holm-Sidak, p<0.05, n=8 for control, n=15 for roscovitine, n=15 for LGR561, n=16 for LGR848, n=8 
for LGR849). 
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4.1.9 Effects of roscovitine and the LGRs on the activity of different Cdks  
To test and compare the selectivity and the potency of roscovitine and its derivatives 
LGR561, LGR848, and LGR849 towards different Cdks, in vitro activity assays for Cdk1, 
Cdk2, CDk4, Cdk5, Cdk7, and Cdk9 were performed. The Cdk5 activity assay was performed 
by Cerep (Paris, France). The activity assays for Cdk1, Cdk2, Cdk4, Cdk7, and Cdk9 were 
performed by ProQinase (Freiburg, Germany). Cdk2, Cdk5, Cdk7, and Cdk9 were strongly 
inhibited by roscovitine. In comparison to roscovitine, its derivatives LGR561, LGR848, and 
LGR849 much more potently decreased the activities of the respective kinases (Table 10). 
LGR561, which has been the most powerful anti-angiogenic agent, decreased the activities of 
the different Cdks most potently in comparison to the mother substance roscovitine and the 
other derivatives LGR848 and LGR 849. This confirms the data concerning the anti-
angiogenic properties of the compounds. 
 
Table 10  In vitro Cdk activity assays. The EC50 values of the different 
compounds towards the indicated Cdks are displayed. 
 
Cdk Roscovitine EC50 [µM] 
LGR561 
EC50 [µM] 
LGR848 
EC50 [µM] 
LGR849 
EC50 [µM] 
Cdk1 4,472 0,422 2,973 2,002 
Cdk2 0,441 0,054 0,265 0,127 
Cdk4 9,173 4,944 18,008 6,263 
Cdk5 1,4 0,4 1,5 1,3 
Cdk7 0,916 0,23 0,647 0,387 
Cdk9 1,431 0,145 0,421 0,268 
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4.1.10 Effects of roscovitine and the LGRs on AKT and ERK 
To elucidate whether the compounds direct kinases beyond the Cdk family, we analyzed their 
influences on two central pathways during cell survival and proliferation: the AKT/PKB 
signalling pathway and the mitogen-activated protein kinases (MAPK) extracellular-signal-
regulated kinases (ERK1/2) pathway. 
AKT, also referred to as protein kinase B (PKB), is essential for various cellular processes 
including apoptosis, survival, cell growth, and proliferation.89 The phosphorylation of AKT 
within the C-terminus at Ser473 is required for its full activation.90 Thus, the impact of 
roscovitine and the LGRs on the phosphorylation of AKT at Ser473 was analyzed. We 
observed a strong induction of the phosphorylation of AKT by FCS (10%) which could not be 
reduced by preincubation with the tested compounds. This suggests that neither roscovitine 
nor its derivatives LGR561, LGR848, and LGR849 inhibit angiogenesis via effecting the 
activation of AKT (Figure 41).  
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Figure 41  Roscovitine and its derivatives have no influence on the phosphorylation of AKT. 
Preincubation with roscovitine (Rosc, 30 µM) (a), LGR561 (10 µM) (b), LGR848 (10 µM) (c), and LGR849 (10 
µM) (d), respectively, did not abolish the FCS (10%) induced phosphorylation of AKT. Levels of phospho-AKT 
(p-AKT, Ser473) and AKT were determined by Western Blot analysis. Representative data out of three 
independent experiments are shown.  
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The extracellular signal-regulated kinases 1 and 2 (ERK1/2) are the most prominent members 
of the family of mitogen-activated protein kinases (MAPK). MAPKs influence cell 
proliferation, differentiation, survival, apoptosis and development.91 ERK1 and 2 are activated 
by dual-specific kinases MEK1/2 via phosphorylation at threonine and tyrosine residues in the 
ERK activation loop.92 The phosphorylation of ERK1/2 was induced by bFGF. Preincubation 
with roscovitine or the LGRs, respectively, did not reduce FGF-induced phosphorylation of 
ERK, suggesting that the anti-angiogenic effects of the compounds are not due to an 
inhibition of ERK activity (Figure 42). 
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Figure 42  Roscovitine and the LGRs do not abolish the phosphorylation of ERK1/2. Preincubation 
with roscovitine (Rosc, 30 µM) (a), LGR561 (10 µM) (b), LGR848 (10 µM) (c), and LGR849 (10 µM) (d), 
respectively, did not abolish the FGF (5 ng/ml) induced phosphorylation of ERK1/2. Levels of phospho-ERK (p-
ERK, Thr202 and Tyr204) and ERK were determined by Western Blot analysis. Representative data out of three 
independent experiments are shown. 
 
 
70  RESULTS 
4.2 Cdk5 is involved in the regulation of endothelial cell migration 
4.2.1 Silencing of Cdk5 reduces endothelial cell migration 
In order to elucidate the mechanisms causing the anti-angiogenic effect of the Cdk inhibitors, 
we analyzed the impact of Cdk2 and Cdk5 on the migration of HUVECs, as endothelial cell 
migration is a key process during angiogenesis.55 Cdk2 and Cdk5 both are prominent targets 
of roscovitine. Cdk2 is an ubiquituously expressed Cdk which regulates cell cycle transitions. 
In contrast, Cdk5 is not implicated in cell cycle control. Since it was discovered in the 1990s, 
it has emerged as a crucial regulator of neuronal migration in the developing nervous system.9  
 
We first checked the expression of Cdk5 in endothelial cells by Western Blot analysis. As 
shown in Figure 43, Cdk5 is expressed in HUVECs. Moreover, proliferating and confluent 
cells display the same amount of Cdk5 protein. 
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Figure 43  Cdk5 is expressed in endothelial cells. Cdk5 was detected by Western Blot analysis. No 
difference of Cdk5 protein level between proliferating and confluent HUVECs was determined. 
 
To selectively inhibit Cdk2 and Cdk5, respectively, we silenced both Cdks using siRNA. 
Successful downregulation of the proteins was determined 24 and 48 h after transfection by 
Western Blot analysis. No cross-reaction was observed (Figure 44 a). In comparison to the 
treatment with non-targeting (nt) siRNA, silencing of Cdk5 led to an inhibition of HUVEC 
migration by 40%. In contrast, the treatment with Cdk2 siRNA showed no significant effect 
(Figure 44 b). To exclude a possible cytotoxic effect of the Cdk5 siRNA, we examined the 
viability of transfected cells by a CellTiter-Blue® assay. The viability of Cdk5 siRNA-treated 
cells was not changed in comparison to nt siRNA-treated cells after 24h or 48h (Figure 44 c).  
 
Taken together, these data suggest an involvement of Cdk5 in the regulation of endothelial 
cell migration.  
 
 
RESULTS  71 
Cdk2
Cdk5
24 h 48 h
β-actin
nt Cdk2 Cdk5nt Cdk2 Cdk5
a
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
nt Cdk5
V
ia
bi
lit
y
(x
-fo
ld
co
nt
ro
l)
24 h
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
nt Cdk5
V
ia
bi
lit
y
(x
-fo
ld
co
nt
ro
l)
48 hc
Cdk5Cdk2ntb
nt Cdk2 Cdk5
0
0.2
0.4
0.6
0.8
1.0
1.2
*
M
ig
ra
tio
n
(x
-fo
ld
co
nt
ro
l)
 
 
 
Figure 44  Silencing of Cdk5 reduces endothelial cell migration. (a) Successful downregulation by 
Cdk2 siRNA (Cdk2), and Cdk5 siRNA (Cdk5) is shown 24 h and 48 h after transfection by Western Blot 
analysis. Non-targeting siRNA (nt) served as control. β-actin served as a loading control (n=3). (b) 
Downregulation of Cdk5 by siRNA decreases endothelial cell migration. In scratch assays, transfection with 
Cdk5 siRNA (Cdk5) significantly decreased the migration of HUVECs, Cdk2 siRNA (Cdk2) had no influence. 
Non-targeting siRNA (nt) served as control. (One Way ANOVA/Dunnett, *p<0.05, n=5). (c) Silencing of Cdk5 
does not influence cell viability. Viability of HUVECs transfected with Cdk5 siRNA is not decreased in 
comparison to cells transfected with nt siRNA (t-test, 24 h: p=0,974, 48 h: p=0,092, n=4). 
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In order to proof the expression of Cdk5 in the endothelium in vivo, histological staining of 
umbilical cords was performed. Cdk5 was colocalized with VE cadherin in the endothelium 
of the umbilical vein (Figure 45).  
Thus, we clearly showed that Cdk5 is expressed in the endothelium in vivo. 
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Figure 45  Cdk5 is expressed in the endothelium in vivo. Histological staining of umbilical cords was 
performed. Two representative stainings are shown. Representative images display the staining of nuclei (blue), 
of Cdk5 (green), and of VE cadherin (red). The overlay (merge) shows colocalization of Cdk5 with VE cadherin. 
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4.2.2 Inhibition of Cdk5 does not influence cell adhesion 
To elucidate the mechanisms of Cdk5 to regulate endothelial cell migration, we first analyzed 
its impact on cell adhesion, one crucial element regulated during cell migration.59 In neuronal 
cells, one reported target of Cdk5 is the Focal Adhesion Kinase (FAK).35 FAK plays a central 
role in cell adhesion and migration. Thus, we investigated the effect of Cdk5 inhibition on the 
phosphorylation of FAK. Phosphorylation of FAK at Ser732, the site which is regulated by 
Cdk5 in neurons,35 indeed was reduced after treatment with roscovitine as well as with Cdk5 
siRNA. Interestingly, FAK autophosphorylation at tyrosine 397 was not affected (Figure 46).  
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Figure 46  Inhibition of Cdk5 decreases the phosphorylation of FAK at Ser732. (a) Roscovitine 
(Rosc, 30 µM) time-dependently decreases the phosphorylation of FAK at Ser732. Phosphorylation at Tyr397 is 
not influenced. (b) Silencing of Cdk5 with siRNA (Cdk5) reduces the phosphorylation of FAK specifically at 
Ser732. Non-targeting siRNA (nt) served as control. (a, b) Phosphorylation of FAK was detected 48 h after 
treatment of HUVECs with Cdk5 siRNA by Western Blot analysis. Total FAK indicates equal loading (n=3) 
 
In order to analyze the functional effects of the Cdk5 driven phosphorylation of FAK at 
Ser732, we analyzed the impact of roscovitine on focal adhesion dynamics and cell adhesion. 
Focal adhesions were visualized by overexpressing eYFP-vinculin. Vinculin is an adapter 
protein present at focal adhesions. Roscovitine caused no difference in focal adhesion 
structure (maturation) as well as in focal adhesion dynamics during cell migration and cell 
spreading. Furthermore, roscovitine did not functionally influence cell adhesion to various 
substrates. 
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Figure 47  Cdk5 inhibition does not influence focal adhesions and cell adhesion. (a) Roscovitine 
neither influences the size, nor the localization, nor the dynamics of focal adhesions during cell migration. 
Images represent migrating HUVECs expressing eYFP-vinculin in the absence (co) or presence of roscovitine 
(Rosc, 30 µM) (n=2). (b) In spreading cells treated with roscovitine no change in focal adhesion localization, 
size, or turnover could be determined. Images represent HUVECs expressing eYFP-vinculin plated for 60 min in 
the absence (co) or presence of roscovitine (Rosc, 30 µM) (n=2). (c) Roscovitine (Rosc, 30 µM) exhibits no 
influence on cell adhesion. HUVECs were plated on differentially coated surfaces in the absence (co) or in the 
presence of roscovitine (Rosc, 30 µM). Adhesion was assessed by crystal violet staining of cells 30 min after 
plating (t-test, n=3). 
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4.2.3 Cdk5 inhibition exerts no effect on the microtubule cytoskeleton 
The phosphorylation of FAK at Ser732 by Cdk5 is important for the organization of 
microtubules in neurons.35 Thus, we analyzed the influence of roscovitine on the structure, 
dynamics, and polymerization of the tubulin cytoskeleton. To analyze microtubule structure, 
scratch assays with HUVECs overexpressing eGFP-tubulin in the absence or the presence of 
roscovitine were performed. Roscovitine had no effect on the structure of microtubules 
(Figure 48 a). To analyze microtubule dynamics, we overexpressed eGFP-CLIP170. CLIP170 
is a microtubule plus-end-tracking protein (+tip) that contributes to cell polarization and 
directional migration by linking microtubule plus-ends to cortical regions.63 Roscovitine did 
not influence microtubule dynamics (Figure 48 b). Furthermore, we performed tubulin 
fractionation assays to analyze possible effects of roscovitine on the polymerization of 
microtubules. In contrast to classical tubulin targeting compounds like taxol or vinblastine, 
roscovitine had no effect on the polymerization of tubulin (Figure 48 c). Altogether, we could 
not determine any effects of roscovitine on the tubulin cytoskeleton. 
 
eGFP β-Tubulin
co
Rosc
a
m
ig
ra
tio
n
b eGFP Clip170
co
Rosc
m
ig
ra
tio
n
 
 
 
76  RESULTS 
T VB Co Rosc
β-tubulin
β-actin
c
 
 
 
Figure 48  Inhibition of Cdk5 has no effect on the tubulin cytoskeleton. (a) Microtubule structure is 
not changed by roscovitine. Images represent HUVECs transfected with eGFP-tubulin after migration of 4 h in 
the absence (co) or presence of roscovitine (Rosc, 30 µM) (n=2). (b) Roscovitine has no influence on the 
dynamics of microtubules. Representative images show HUVECs expressing eGFP-CLIP170 during migration 
in the absence (co) or presence of roscovitine (Rosc, 30 µM) (n=2). (c) Roscovitine (Rosc, 30 µM) has no effect 
on the polymerization of tubulin. Taxol (T) and vinblastine (VB) showed the expected stabilization or 
fragmentation of microtubules, respectively. Fractions of polymerized tubulin are shown. β-actin indicates equal 
loading (n=3). 
 
 
4.2.4 Cdk5 inhibition influences the actin cytoskeleton 
Actin is a major component of the cytoskeleton. The constant remodeling of actin filaments 
during the formation of lamellipodia, filopodia and stress fibres is essential for cell 
migration.55, 64 In order to investigate whether Cdk5 influences the actin cytoskeleton in 
endothelial cells we performed scratch assays and stained F-actin in migrating cells with 
rhodamine/phalloidin. Untreated cells as well as cells treated with nt siRNA formed 
lamellipodia with a densely packed actin seam at the leading edge, whereas cells treated with 
roscovitine or Cdk5 siRNA displayed a strong reduction of lamellipodia (Figure 49 a). 
Additionally, the inhibition of Cdk5 reduced the localization of cortactin, a protein regulating 
the protrusion and integrity of lamellipodia, to the leading edge (Figure 49 b).72, 73 
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Figure 49  Cdk5 inhibition influences the actin cytoskeleton. (a, b) Inhibition of Cdk5 with roscovitine 
(Rosc, 30 µM) as well as silencing with Cdk5 siRNA (Cdk5) reduces the formation of lamellipodia during 
migration. Untreated cells are indicated as control (co), non-targeting siRNA as nt. (a) Images show migrating 
HUVECs stained for F-actin (n=3). (b) Images represent migrating cells stained with anti-cortactin antibodies 
(n=3). 
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4.2.5 Cdk5 inhibition regulates the small Rho GTPases RhoA and Rac1 
In order to get insights into the signalling mechanisms underlying the effect of Cdk5 on 
remodeling of the actin cytoskeleton, we examined the impact of roscovitine on the activity of 
RhoA and Rac1, the most prominent regulators of the actin cytoskeleton during cell 
migration.59  
Applying pull down assays, roscovitine highly increased levels of GTP-bound RhoA, 
suggesting an enhanced RhoA activity (Figure 50 a). This was accompanied by a decrease of 
p27kip1 protein expression after Cdk5 inhibition with roscovitine (Figure 50 b) or Cdk5 siRNA 
(Figure 50 c), respectively. p27kip1 is classically known as CKI, but it also modulates cell 
migration by preventing RhoA activation.93 In neurons, p27kip1 gets phosphorylated and 
stabilized by Cdk5, contributing to actin organization and neuronal migration.33 
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Figure 50  Roscovitine increases the activity of RhoA. (a) In pull-down assays, roscovitine (Rosc, 30 
µM) increased the amount of RhoA-GTP. Untreated cells are indicated as control (co) (n=3). (b) Roscovitine 
(Rosc, 30 µM) as well as (c) Cdk5 siRNA (Cdk5) decreased p27kip1 protein levels, in comparison to untreated 
cells (co) or cells transfected with nt siRNA (nt), respectively. Blotting for β-actin indicates equal loading. (n=3). 
 
To determine whether the impaired endothelial cell migration upon Cdk5 inhibition is due to 
the increase in RhoA activity, we performed scratch assays with Y27632, an inhibitor of the 
RhoA downstream kinase ROCK I. Preincubation with the ROCK I-inhibitor Y27632 did not 
significantly abolish the inhibition of migration caused by roscovitine (Figure 51). This 
suggests that Cdk5 does not regulate endothelial cell migration via activation of the RhoA – 
ROCK I - pathway. 
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Figure 51  Inhibition of ROCK I does not rescue the effect of roscovitine on endothelial cell 
migration. Preincubation with Y27632 (10 µM) does not significantly abolish the effect of roscovitine (Rosc, 30 
µM) on the migration of HUVECs. Representative images are shown. (not significant, ns), One Way 
ANOVA/Holm-Sidak, n=3). 
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Rac1 is a crucial regulator for lamellipodia formation and cell migration.59 Applying pull-
down assays, we detected a strong reduction of GTP-bound Rac1 upon treatment with 
roscovitine, suggesting a reduced Rac1 activity (Figure 52 a). In live cell imaging experiments 
with cells overexpressing eYFP-Rac1, we analyzed the distribution of Rac1 during cell 
spreading. Untreated cells displayed a regular cell shape with Rac1 localized to lamellipodia. 
In contrast, in cells treated with roscovitine, Rac1 was distributed over the whole cell which 
was accompanied by an irregular cell shape with large extensions of the cytoplasm and 
formation of ruffles (Figure 52 b). In contrast, the formation of filopodia seems not to be 
influenced upon inhibition of Cdk5 (Figure 52 c), suggesting that Cdc42 which regulates the 
formation of filopodia is not involved in the signalling of Cdk5 in endothelial cell migration.59 
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Figure 52  Inhibition of Cdk5 decreases Rac1 activity and inhibits its localization to lamellipodia.  
(a) Roscovitine decreases the activity of Rac1. In pull-down assays, roscovitine (Rosc, 30 µM) reduced the 
amount of Rac1-GTP. Untreated cells are indicated as control (co) (n=3). (b) During cell spreading, roscovitine 
inhibits the localization of Rac1 to lamellipodia. Images show HUVECs expressing eYFP-Rac1 in the absence 
(co) or presence of roscovitine (Rosc, 30 µM) 60 min. after plating. Spreading cells treated with roscovitine 
display an irregular shape with Rac1 distributed over the cytoplasm (n=3). (c) Roscovitine seems not to 
influence the formation of filopodia. Filopodia could be visualized in HUVECs that extremely strong 
overexpress eYFP-Rac1. Images show HUVECs in the absence (co) or presence of roscovitine (Rosc, 30 µM) 60 
min. after plating. Untreated cells (co) and roscovitine treated cells (Rosc) both form filopodia. 
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Furthermore, the inhibition of Cdk5 by treatment with roscovitine as well as with siRNA 
abolished the colocalization of Rac1 and cortactin, a protein that is crucial for the formation 
and integrity of lamellipodia, at the leading edge of migrating cells (Figure 53 a, b). These 
data suggest that Cdk5 regulates endothelial cell migration via influencing the actin 
cytoskeleton by activation of Rac1. 
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Figure 53  Inhibition of Cdk5 inhibits colocalization of Rac1 and cortactin at lamellipodia. 
Roscovitine (Rosc, 30 µM) (a) as well as Cdk5 siRNA (Cdk5) (b) inhibit colocalization of Rac1 and cortactin at 
lamellipodia during migration in comparison to untreated cells (co) as well as cells transfected with nt siRNA 
(nt). Images represent migrating cells stained for Rac1 (green) and cortactin (red) (n=3). The colocalization 
(yellow) is shown in the overlay (merge). 
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5 DISCUSSION 
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Angiogenesis, the formation of new blood vessels from existing ones, is a prerequisite for 
tumor growth and progression. Thus, in addition to the treatment of cancer cells with anti-
proliferative compounds, anti-angiogenic therapy which is aimed to antagonize tumor derived 
blood vessel formation, represents a promising approach in oncology.3 Many anti-angiogenic 
agents are currently tested in clinical trials and some have already been approved for cancer 
therapy. At present, inhibitors of the VEGF pathway are in the centre of clinical interest. They 
are very promising anti-angiogenic agents which stop the growth of tumor vessels, cause 
regression of existing vessels, normalize surviving vessels, and thus, provoke regression of 
the tumor itself. Consequently, they demonstrate therapeutic efficacy in an increasing number 
of human cancers.2 However, in both preclinical and clinical settings, the benefits of existing 
anti-angiogenic agents are at best transitory and followed by a restoration of tumor growth 
and progression. Recently, two different modes of resistance to anti-angiogenic therapy were 
described. Adaptive resistance refers to the ability of the tumor, after an initial phase of 
response, to circumvent the specific angiogenic blockade, leading to renewed tumor growth 
and progression. Intrinsic non-responsiveness means the pre-existing indifference of the 
tumor towards anti-angiogenic therapy.94 This resistance to anti-angiogenic therapy indicates 
a great need for new targets and treatment strategies to inhibit angiogenesis. 
Cyclin dependent kinases (Cdks) are key regulators of cell proliferation. Since Cdk 
deregulation was found in most cancer cells, pharmacological inhibition of Cdks has become 
an attractive strategy in cancer therapy.50 Over the last decade, a variety of agents has been 
developed to inhibit Cdks, and thus, to block cell cycle progression, to decrease proliferation, 
and to induce apoptosis in cancer cells. So far, some of these drugs have reached clinical 
evaluation for cancer therapies, including flavopiridol (Aventis), 7-hydroxystaurosporine 
(Kyowa Hakko Kogyo), and roscovitine (Cyclacel Pharmaceuticals). Surprisingly, very little 
is known about the effects of Cdk inhibitors on endothelial cells and angiogenesis. Only a few 
published results indicate potential anti-angiogenic properties of these agents. Flavopiridol, a 
non-specific Cdk inhibitor, was determined to induce apoptosis in HUVECs,95 and to decrease 
blood vessel formation in an in vivo Matrigel® model.96 Roscovitine was shown to inhibit 
proliferation and to induce apoptosis in bovine aortic endothelial cells (BAEC).97 However, 
no in-depth-studies concerning the detailed mode of action, or identifying the respective Cdk 
and its substrates, have been performed to date. 
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5.1 Anti-angiogenic effects of the established Cdk inhibitor roscovitine and 
its new derivatives LGR561, LGR848, and LGR849 
This work supports the idea of the application of Cdk-inhibitors as anti-angiogenic agents. For 
the first time we elucidate that the Cdk inhibitor roscovitine exerts anti-angiogenic effects in 
vitro and in vivo. Our work for the first time gives insights into the mechanism of roscovitine 
to disrupt the angiogenic cascade. 
Moreover, the present study gives a first clue how the chemical structure of roscovitine could 
be optimized to increase its anti-angiogenic potency. In comparison to the mother substance 
roscovitine, its derivatives LGR561, LGR848, and LGR849 inhibited angiogenesis much 
more potently, especially LGR561 and LGR849. LGR561 was the most powerful anti-
angiogenic agent. Thereby, the anti-angiogenic activity of roscovitine and its derivatives can 
be traced back to the fact that they inhibit Cdks. Neither the AKT/PKB signalling pathway 
nor the MAPK/ERK1/2 cascade, both central elements during cell survival and proliferation, 
was disrupted by the compounds.89, 91 Furthermore, the anti-angiogenic activity of the 
respective compounds coincides with their potency to inhibit Cdks. In Cdk activity assay, 
LGR561 also was the most potent compound, followed by LGR849. LGR848 was only 
slightly more powerful than roscovitine. No preference of the LGRs to inhibit one certain Cdk 
could be distinguished: they inhibited Cdk1, Cdk2, Cdk5, Cdk7, and Cdk9, just as 
roscovitine. However, compared to the other compounds, the most effective anti-angiogenic 
agent LGR561 displayed a higher potency towards Cdk5. This suggests that the additional 
ortho-hydroxyl-group in the benzyl function of LGR561 optimizes the potency and the 
selectivity of roscovitine towards Cdk5. The meta-methoxy-group does not seem not be 
advantageous. The effectiveness of LGR561 to inhibit angiogenesis is reduced by the 
accessorily added meta-methoxy-group in LGR849 and LGR848.  
The higher anti-angiogenic capacity of the (S)-stereoisomer LGR849 compared to the 
appropriate (R)-stereoisomer LGR848 is surprising. A comparison of the relative activities of 
the (R) and (S) stereoisomers of roscovitine towards Cdk1/cyclin B has indicated that the (R)-
stereoisomer has about twice the inhibitory capacity than the (S)-stereoisomer, although this 
difference was barely detectable towards Cdk2/cyclinE.54 Thus, both for in vitro and in vivo 
experiments and for clinical trials as well, investigators use and apply the (R)-stereoisomer 
whereas the (S)-stereoisomer never has drawn notable attention. Based on these data 
concerning the potencies of the stereoisomers of roscovitine to inhibit Cdks, we had estimated 
a higher anti-angiogenic capacity of the (R)-stereoisomer LGR848 in comparison to the (S)-
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stereoisomer LGR849. A possible explanation for the higher potency of the (S)-stereoisomer 
might be a different type of binding of the LGR-compounds to the catalytic centre of Cdks, 
compared to roscovitine, due to the additional functional groups on the benzyl function. 
Furthermore, the isomers may partly form the racemate in solution.  
 
Altogether, we elucidate for the first time that the Cdk inhibitor roscovitine exerts anti-
angiogenic effects. This suggests a possible new application of Cdk inhibitors as anti-
angiogenic agents. Moreover, we show that the new Cdk inhibitors LGR561, LGR848, and 
LGR849 inhibit the angiogenic cascade more powerfully, in comparison to the mother 
substance roscovitine. This gives a first clue to optimize the chemical structure of roscovitine 
to increase its anti-angiogenic potency. 
 
5.2 Cdk5 is involved in the regulation of endothelial cell migration 
To get insights into the mechanisms causing the anti-angiogenic effects of the Cdk inhibitors, 
we analyzed the influence of Cdk2 and Cdk5 on endothelial cell migration. The migration of 
endothelial cells plays a pivotal role during angiogenesis.55 Cdk2 and Cdk5 both are 
prominent and well defined targets of roscovitine.6, 7 They share about 60% sequence 
homology and partly have overlapping protein substrate specificity.9 We focused on Cdk2 as 
a representative of the classical cell cycle related kinases which regulate cell cycle transitions 
and on Cdk5 based on its role in the developing nervous system, where it is essential for the 
regulation of neuronal cell migration.9  
Roscovitine at concentration of 10 µM inhibits angiogenesis, but has no effect on the cell 
cycle. This suggests that a non cell cycle-related Cdk is involved in the regulation of 
endothelial cell migration. In fact, using siRNA to specifically downregulate Cdk2 and Cdk5, 
respectively, we elucidated an entirely new function of Cdk5 in the endothelium: we 
determined an involvement of Cdk5 in the regulation of endothelial cell migration. In contrast 
to Cdk5, Cdk2 was not involved in the regulation of cell migration. This suggests that the 
anti-angiogenic effects of roscovitine and its derivatives, the LGR-compounds, are most likely 
due to their inhibition of Cdk5 activity.  
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5.2.1 Influence of Cdk5 on cell adhesion, on microtubules and on the actin cytoskeleton  
To reveal the mechanisms of Cdk5 to regulate endothelial cell migration, we analyzed its 
impact on the three superordinated elements regulated during migration: on cell adhesion, on 
the organization of microtubules and on the remodelling of the actin cytoskeleton. Cell 
migration is a complex process that results from coordinated changes in cell-substratum 
adhesions and the cytoskeleton. The microtubule network assumes a regulatory function by 
maintaining cell polarity. The actin cytoskeleton provides the driving force by remodelling 
into lamellipodia and filopodia at the leading edge and by the formation of stress fibres at the 
sides and the rear of the migrating cell. The formation of new adhesions to the ECM under the 
leading edge stabilizes the cell front whereas existing adhesions at the trailing edge are 
disrupted to allow cell detachment and forward crawling.55, 61, 98  
In developing cell adhesions, FAK plays a pivotal role. It is a component of focal adhesions 
and focal complexes, serves as an adapter protein and is involved in integrin-mediated signal 
transduction. In response to growth factors or integrin clustering, FAK is regulated by 
phosphorylation at various tyrosine and serine residues.75, 99 By analyzing the impact of the 
inhibition of Cdk5 on FAK, we determined a decrease in the phosphorylation of FAK at 
Ser732. In contrast, the autophosphorylation of FAK at Tyr397, which is required for the 
catalytic activity of FAK, was not affected.75 Le Boeuf et al. found that a FAK mutant not 
phosphorylatable at Ser732 abrogates the recruitment of vinculin, an adapter protein present at 
focal adhesions, to the ventral focal adhesions.76 In contrast, we could not observe a link 
between the reduced phosphorylation of FAK at Ser732 and a change in the formation of 
focal adhesions, both during cell migration and cell spreading. This lack of an effect was 
mirrored by the fact that roscovitine did not functionally influence cell adhesion on various 
substrates. 
Several reports concerning the role of Cdk5 in neurons indicate an influence of Cdk5 on 
microtubules.35, 36 Xie et al. showed that Cdk5-mediated phosphorylation of FAK at Ser732 is 
required for nuclear movement and neuronal migration via influencing microtubule 
organization.35 Although Cdk5 inhibition led to a decreased phosphorylation of FAK at 
Ser732 in endothelial cells as well, neither microtubules structure, nor dynamics, stability, or 
polymerization was modified. The previously described fact that the phosphorylation of FAK 
at Ser732 does not influence its kinase activity,35 might be a possible explanation. Taken 
together, we neither found an effect of Cdk5 on cell adhesion nor on the organization of 
microtubules. 
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Finally, we analyzed the influence of Cdk5 on the organization of the actin cytoskeleton in 
endothelial cells. The constant remodelling of the actin cytoskeleton represents the driving 
force during cell migration. Thus, an effect on its organization would result in a changed 
motility.98 The fact that roscovitine inhibits cell motility per se in chemotaxis assay, displays a 
first hint for an effect of Cdk5 on the actin cytoskeleton. Indeed, our hypothesis could be 
confirmed: in HUVECs, the inhibition of Cdk5 caused a reduced formation of lamellipodia 
during migration. Lamellipodia are broad sheet-like membrane protrusions which are formed 
by the polymerization of actin into highly branched filaments. They are generated at the 
leading edge of migrating cells.64 At the lamellipodium, new adhesions are formed connecting 
the actin cytoskeleton to the extracellular matrix which anchors the front of the cell and 
enables it to crawl forward. Thus, the formation of a lamellipodium is a prerequisite for 
proper cell migration.66 Our work identifies Cdk5 to be required for the formation of 
lamellipodia in endothelial cells. This denotes that Cdk5 regulates endothelial cell migration 
via an involvement in the remodelling of the actin cytoskeleton.  
 
5.2.2 Influence of Cdk5 on RhoA and Rac1 
In order to investigate the mechanism of Cdk5 to regulate the actin cytoskeleton, we had a 
closer look at RhoA and Rac1, two members of the family of small Rho GTPases. Small Rho 
GTPases were proven as crucial regulators of the actin cytoskeleton in various cell types. 
During migration, Rac1 is active at the cell front, where it promotes the extension of 
lamellipodia. In contrast, RhoA is active at the sides and the rear of the cell, associated with 
stress fiber formation and cell body contraction.59, 65, 67 Thus, RhoA and Rac1 are mutually 
antagonistic, thereby maintaining cell polarity and regulating cell migration.74  
In neurons, Cdk5 is involved in the regulation of Rho GTPases. Cdk5 was shown to 
phosphorylate and stabilize p27kip1 which suppresses RhoA activity. This leads to an increase 
in non-phosphorylated, activated cofilin, required for the organization of actin filaments 
during neuronal migration.33 Furthermore, it was reported that Cdk5 associates with PAK1 in 
a Rac1-dependent manner, causing phosphorylation and down-regulation of PAK1 kinase 
activity, which promotes neuronal migration and neurite outgrowth and affects neuronal 
morphology.27, 28  
In endothelial cells, RhoA and Rac1 both seem to be regulated by Cdk5. The inhibition of 
Cdk5 increased RhoA activity concomitant to a decrease of p27kip1 protein levels. p27kip1 is 
classically known as CKI but it also regulates cell migration by preventing RhoA activation. 
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However, Y27632, an inhibitor of ROCK-I, the most prominent downstream effector of 
RhoA, could not compensate for the inhibiting effect of roscovitine on endothelial cell 
migration. In contrast, Besson et al. showed that inhibition of ROCK-I rescued the migration 
defect of p27kip1 –null cells.93 Our data suggest that Cdk5 indeed regulates RhoA activity. 
Nevertheless, Cdk5 seems not to regulate endothelial cell migration exclusively via the p27kip1 
– RhoA – ROCK-I pathway. Our data point to an additional/another downstream target of 
Cdk5 that is involved in the regulation of endothelial cell migration.  
In fact, the inhibition of Cdk5 strongly reduced Rac1 activity. Moreover, the colocalization of 
Rac1 and cortactin at the leading edge of migrating endothelial cells was impaired upon Cdk5 
inhibition. Cortactin is an Arp2/3 complex and F-actin binding protein, that plays a pivotal 
role in lamellipodia protrusion and integrity.72 Tyrosine-phosphorylation of cortactin, which is 
required for efficient cell motility, is dependent on the targeting of cortactin to the cortical 
actin network (lamellipodia) that in turn is regulated by the activation state of Rac1.73 Our 
data clearly indicate that Cdk5 is required for the activation of Rac1 and, in turn, for the 
localization of Rac1 and cortactin to lamellipodia. 
 
Altogether, our work for the first time elucidates a novel function of Cdk5 in endothelial cells. 
We found that Cdk5 is involved in the regulation of endothelial cell migration. Cdk5 is 
required for the formation of lamellipodia by influencing the remodelling of the actin 
cytoskeleton. It activates the small Rho GTPase Rac1 and regulates the localization of Rac1 
and its downstream target cortactin to the leading edge of migrating cells.  
 
5.3 Possible aspects of future research 
Importantly, this work opens a new field of research with two central questions: 
1. How does Cdk5 activate Rac1? 
Is the Rac1 activation by Cdk5 due to the Cdk5 induced RhoA inhibition? RhoA and Rac1 can 
suppress each other’s activity, acting antagonistic.74 A recently recognized mediator of the 
antagonism of Rac1 by RhoA is FilGAP. FilGAP is a filamin A-binding RhoGTPase-
activating protein that gets phosphorylated and activated by the RhoA downstream-effector 
ROCK I. This phosphorylation stimulates its GAP activity towards Rac1 and leads to Rac1 
inactivation, suppressing leading edge protrusion and promoting cell retraction.100  
However, we excluded the RhoA-ROCK I pathway to be the direct mediator of Cdk5 in the 
regulation of endothelial cell migration, suggesting that this theory is rather unlikely. 
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Does Cdk5 directly activate Rac1 e.g. by regulating a Rac1 specific GEF or GAP? Guanine 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) directly regulate 
the activation state of Rho GTPases. In neurons, Cdk5 was reported to regulate several GEFs. 
For example, Cdk5 phosphorylates Ras guanine nucleotide releasing factor-1 (Ras GRF1) and 
Ras guanine nucleotide releasing factor-2 (Ras GRF2), both GEFs responsible for the 
activation of Ras and Rac GTPases. Cdk5 mediated phosphorylation causes Ras GRF1 
degradation and thus, reduces Ras activity. Phosphorylation of Ras GRF2 by Cdk5 leads to its 
inactivation, downregulating Ras GRF2-mediated Rac1 activity. Furthermore, Cdk5 was 
shown to activate ephexin1, a GEF that regulates the activation of RhoA.31 These reports 
confirm the possibility that in endothelial cells, Cdk5 regulates Rac1 via (a) specific GEF(s) 
or GAP(s).  
 
Does Cdk5 regulate Rac1 by influencing its spatial distribution? Cell motility critically relies 
on localized signalling. Studies on Rac1 suggested that the control of its intracellular traffic is 
important for determining the sites at wich Rac1 signalling occurs.101 Recently, Palamidessi et 
al. showed that endocytic trafficking of Rac1 is required for the spatial restriction of 
signalling in cell migration. They reported, that the process of endocytosis controls actin 
dynamics via Rac1.102 Furthermore, Cdk5 was determined to be an important regulator of 
synaptic vesicle endocytosis via phosphorylation of dynamin I, a GTPase whose activity is 
essential for synaptic vesicle fission.103 The hypothesis that Cdk5 regulates Rac1 via its 
spatial distribution is strengthened by our data which show that the inhibition of Cdk5 impairs 
the localization of Rac1 to lamellipodia.  
 
2. How is Cdk5 itself regulated in migrating endothelial cells?  
Which relevance do p35 and p39, the neuronal activators of Cdk5, have in endothelial cells? 
By PCR experiments, we could show that p35 is expressed in endothelial cells (data not 
shown). This might suggest that p35 also regulates the activity of Cdk5 in endothelial cells. 
 
Where is Cdk5 localized during migration? In cultured neurons, Cdk5 and p35 were shown to 
colocalize with F-actin and to concentrate at the leading edges of axonal growth cones, 
regulating neurite outgrowth.104 Furthermore, p39 colocalizes with actin in cultured cells and 
coimmunoprecipitates with actin in brain lysates.105 Thus, Cdk5 might be colocalized with F-
actin at lamellipodia in migrating endothelial cells. 
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Is Cdk5 activity regulated by pro-angiogenic stimuli like growth factors? In neurons, Cdk5 is 
activated by phosphorylation at Tyr15. C-Abl, a nonreceptor tyrosine kinase related to the Src 
family, phosphorylates Cdk5 at Tyr15, increasing its kinase activity. Cables, a substrate of c-
Abl, interacts with Cdk5 and enhances its phosphorylation.106 The role of phosphorylation of 
Cdk5 by CAK is not entirely clear.9 In neurons, Cdk5 kinase activity is also stimulated by 
Neuregulin, a growth factor that activates ErbB receptors which belong to the epidermal 
growth factor receptor related family of tyrosine kinases.107 These reports suggest that in 
endothelial cells, Cdk5 might get activated by pro-angiogenic signals like VEGF or bFGF. 
 
Is Cdk5 regulated by Cdk inhibitors (CKIs)? The CKIs p21waf1/kip1and p27kip1 which 
effectively inhibit Cdk2 have only minimal effect on p35/Cdk5.9 Analysis of bovine brain 
extracts by gel-filtration chromatography yield an inactive p35/Cdk5 complex that is part of a 
macromolecular structure. An active p35/Cdk5 complex was obtained by subjecting the 
complex to gel-filtration chromatography in the presence of ethylene glycol, indicates that the 
macromolecular complex could contain a Cdk5 inhibitory factor.108 However, no CKI for 
Cdk5 has been identified to date. 
 
5.4 Conclusion 
In conclusion, we identified the well-established Cdk inhibitor roscovitine as a new anti-
angiogenic agent, suggesting a possible new application of Cdk inhibitors as anti-angiogenic 
agents.  
The comparison of the anti-angiogenic potencies of roscovitine with its new derivatives 
LGR561, LGR848, and LGR849 gives a first clue for the optimization of the chemical 
structure of roscovitine to improve its anti-angiogenic properties. The addition of an ortho-
hydroxyl-group in the benzyl function of roscovitine could contribute to develop even better 
new anti-angiogenic agents. 
Interestingly, we elucidated for the first time an involvement of Cdk5 in endothelial cell 
migration. We found that Cdk5 regulates the organization of the actin cytoskeleton by 
influencing the formation of lamellipodia via Rac1.  
 
Thus, our work highlights both the novel possibility of using Cdk inhibitors as anti-
angiogenic agents, and Cdk5 as a new target for anti-angiogenic therapy. This novel role of 
Cdk inhibitors gives a first clue for their application in anti-angiogenic therapy to broaden the 
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spectrum and to overcome the drawbacks of already existing inhibitors of angiogenesis in 
oncology and other pathological processes involving excessive angiogenesis. Moreover, the 
dual effect of roscovitine on the cell cycle of tumor cells and tumor vascularization could be 
important in understanding its therapeutic efficacy under various clinical conditions. 
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Anti-angiogenic agents have successfully been approved for the treatment of several 
disorders, including diabetic retinopathy, arthritis, psoriasis, and cancer. However, the 
benefits of existing anti-angiogenic agents are at best transitory and followed by a restoration 
of tumor growth and progression. This resistance to anti-angiogenic therapy indicates a great 
need for new targets and treatment strategies to inhibit angiogenesis.  
 
Our work supports the idea of the application of Cdk-inhibitors as a novel class of anti-
angiogenic compounds. We show for the first time that the clinically well-established Cdk 
inhibitor roscovitine exerts anti-angiogenic effects in vitro and in vivo.  
 
Furthermore, our work gives a first clue for optimizing the chemical structure of roscovitine 
to improve its anti-angiogenic properties. In comparison to their mother substance 
roscovitine, the new Cdk inhibitors LGR561, LGR848, and LGR849 - especially the (S)-
stereoisomer LGR561 - inhibited angiogenesis much more potently (Figure 54).  
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Figure 54  Roscovitine, LGR561, LGR848, and LGR849 inhibit angiogenesis in vitro and in vivo. In 
comparison to the mother substance roscovitine, the LGRs are more powerful. LGR561 most potently disrupts 
the angiogenic cascade. 
 
SUMMARY  95 
By selectively analyzing the influence of Cdk2 and Cdk5 - both prominent and well defined 
targets of roscovitine6, 7 - on endothelial cell migration, a key process during angiogenesis,55 
we elucidate an entirely new function of Cdk5 in the endothelium: an involvement of Cdk5 in 
the regulation of endothelial cell migration. 
 
In migrating endothelial cells, Cdk5 influences the organization of the actin cytoskeleton by 
regulating the formation of lamellipodia via Rac1 and its downstream target cortactin.  
Cdk5 also modulates the activity of RhoA via p27kip1, but it does not regulate endothelial cell 
migration directly via the RhoA - ROCK I pathway. Furthermore, Cdk5 phosphorylates FAK 
at Ser732. However, its impact on endothelial cell migration is not clear. Finally, Cdk5 
neither influences the microtubule network nor cell adhesion.  
 
Figure 55 gives an overview over the signalling of Cdk5 in endothelial cell migration. 
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Figure 55  Signalling of Cdk5 in endothelial cell migration.  
 
Thus, the anti-angiogenic effects of roscovitine and its derivatives LGR561, LGR848, and 
LGR849 are most likely due to their inhibition of Cdk5 activity. 
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In conclusion, our work  
1. highlights the potential new therapeutic indication of Cdk inhibitors as anti-
angiogenic agents, 
 
2. elucidates a novel role of Cdk5 in endothelial cell migration indicating Cdk5  
as a new target for anti-angiogenic therapy, and  
 
3. is the basis for a new field of research with the two central questions:  
How are Cdk5 and Rac1 functionally connected?  
How is Cdk5 itself regulated in migrating endothelial cells? 
 
 
 
This work was supported by the EU-project PROKINASE No 503467. 
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8.1 Abbreviations 
ALS    amyotrophic lateral sclerosis 
AKT     proteinkinase B 
APS     ammonium persulfate 
Arp2/3    actin-related protein-2/3 
ATP     adenosine-5’-triphosphate 
BSA     bovine serum albumin 
c-Abl    c-Abelson 
CAM     chick chorioallantoic membrane 
CAPS     cyclohexylamino-1-propane sulfonic acid 
CCD     charge-coupled device 
cdc    cell division cycle 
CAK    Cdk-activating kinase 
Cdk    cyclin dependent kinase 
CKI    Cdk inhibitor 
CLASP   CLIP-associating protein 
CLIP    cytoplasmic linker protein 
CLSM    confocal laser scanning microscopy 
DMSO    dimethyl sulfoxide 
DNA     deoxyribonucleic acid 
ECGM    Endothelial Cell Growth Medium 
ECL     enhanced chemoluminescence 
ECM    extracellular matrix 
ECs     endothelial cells 
EDTA    ethylenediaminetetraacetic acid 
EGTA    ethylene glycol tetraacetic acid 
ERK     extracellular signal-regulated kinase 
FACS     fluorescence activated cell sorter 
FAK    focal adhesion kinase 
FCS     foetal calf serum 
FGF     fibroblast growth factor 
FL2-H    fluorescent channel 2 height 
FSC     forward scatter 
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GAP    GTPase activating protein 
GDI    guanine nucleotide dissociation inhibitor 
GEF    guanine nucleotide exchange factor 
GDP    guanosin-5’-diphosphate 
GRF    guanine nucleotide releasing factor 
GTP    guanosin-5’-triphosphate 
h     hour 
HFS     hypotonic fluorochrome solution 
HMEC    human microvascular endothelial cell 
HRP     horseradish peroxidase 
HUVEC    human umbilical vein endothelial cell 
LIMK    LIM kinase 
MAP    microtubule associating protein 
MAPK    mitogen-activated protein kinase 
mDia    mammalian diaphanous protein 
MEK     MAPK/ERK kinases 
min     minute 
MLC    myosin light chain 
MLCP    MLC phosphatase 
mRNA    messenger RNA 
MTOC   microtubule orginizing centre 
PAA     polyacrylamide 
PAGE     polyacrylamide gel electrophoresis 
PAK    p21 activated kinase 
PAR-complex   polarity protein partitioning-defective-complex 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PDGF    platelet derived growth factor 
PI     propidium iodide 
PI3K     phosphoinositide 3-kinase 
PKA     protein kinase A 
PKC    protein kinase C 
PMSF     phenylmethylsulphonyl fluoride 
PVDF     polyvinylidene fluoride 
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RNA     ribonucleic acid 
ROCK    Rho associated kinase 
Rosc    roscovitine 
SDS     sodium dodecyl sulfate 
SDS-PAGE    sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM     standard error of the mean value 
Ser     serine 
siRNA    small interfering RNA 
TE     tris-EDTA buffer 
TEMED    N, N, N’, N’ tetramethylethylene diamine 
Thr     threonine 
+Tip    plus-end tracking protein 
TNF-α    tumor necrosis factor-α 
Tris     trishydroxymethylaminomethane 
Tyr     tyrosine 
VEGF     vascular endothelial growth factor 
WASP    Wiskott Aldrich syndrome protein 
WAVE   WASP-family verprolin-homologous protein complex 
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8.2.2 Oral communication 
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